Corrections
When a number here turns out to be wrong we change it and say so, with what it used to say. A comparison site that edits a price quietly is asking to be trusted on exactly the thing it just got wrong.
Found something wrong? Say so in the box at the foot of the page it is on, or write to corrections@halfrx.com, and it lands on this page.
What we get wrong
Of the 272 changes below, 140 were prices, 71 were something the FDA label says and 16 were what a state publishes about covering these drugs. 2 were about how the score itself is built. 43 were other claims about a seller. Prices fail here most, and label facts next, which is not the split you would guess: a label is a fixed public document and a price is not, and we still misread the fixed one 71 times.
16 of the 140 price corrections came from repeating a third-party report instead of reading what the seller publishes. In 21 more the figure was right in the table and stale in the sentence beside it, because a price has two writers here and only one of them had run. Of the remaining 103, many are the kind worth knowing about: a real, published figure that covered less than a reader would assume. A titration month priced as the drug. A membership fee with the medication charged on top. A per-visit charge quoted as a monthly one. An offer whose expiry had already passed.
That is the thing worth carrying to any GLP-1 price you read, here or anywhere: the number is usually real, and the question is what it covers. Ask which dose it is for, whether the consultation is inside it, how many fills it lasts and what date it ends. 263 of the 272 corrections below link the outside page the new figure was read from; 9 link a page on this site instead.
- 2026-09-14PlushCareThe membership-fee answer on the PlushCare page said the price here adds the fee and the medication.
- Now
- The fee alone is not what a month costs, and no monthly total for PlushCare is recorded here.
- Why
- The PlushCare card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- 2026-09-14WeightWatchers ClinicThe membership-fee answer on the WeightWatchers Clinic page said the price here adds the fee and the medication.
- Now
- The fee alone is not what a month costs, and no monthly total for WeightWatchers Clinic is recorded here.
- Why
- The WeightWatchers Clinic card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- 2026-09-14Hims & HersThe membership-fee answer on the Hims & Hers page said the price here adds the fee and the medication.
- Now
- The fee alone is not what a month costs, and no monthly total for Hims & Hers is recorded here.
- Why
- The Hims & Hers card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- 2026-09-14Ro BodyThe membership-fee answer on the Ro Body page said the price here adds the fee and the medication.
- Now
- The fee alone is not what a month costs, and no monthly total for Ro Body is recorded here.
- Why
- The Ro Body card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- Was
- Requires a paid Sam's Club membership
- Now
- No membership is needed to buy prescription medications
- Why
- The card said a paid Sam's Club membership was required. Sam's Club's help center says you do not have to be a member to buy prescription medications there.
- Was
- The Member Health program page stopped resolving; no price is left to verify
- Now
- Sam's Club Pharmacy's own page prices Zepbound KwikPens at $299 to $699 a month by dose
- Why
- The card said the Sam's Club help-center page it was built on answered only an error, so no price was shown. The page answers again, and prices Zepbound KwikPens through Sam's Club Pharmacy at $299 to $699 a month by dose with the manufacturer's coupon.
- Was
- No page of its could be read, so whether it names a compounding pharmacy was unknown
- Now
- Names Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding as its partner pharmacies
- Why
- No page of MEDVi's could be read when this was last checked, on 10 September 2026. Its site, now at medvi.org, lists three partner pharmacies with their addresses in its footer.
- Was
- No longer a telehealth site: medvi.com serves a parked-domain stub
- Now
- Trades from medvi.org: compounded semaglutide at $149 for the first month, refills at $299
- Why
- The card said MEDVi was no longer a telehealth site because medvi.com served a parked-domain stub. MEDVi trades from medvi.org, whose program page prices compounded semaglutide at $149 for the first month and $299 a refill.
- Was
- The domain is for sale and there is nothing left to read a price from
- Now
- Trades from tryshed.com: semaglutide from $159 or $249 a month, tirzepatide from $239 or $349, as its own pages print them
- Why
- The card said Shed's site was gone because shed.com lands on a domain broker's for-sale page. Shed trades from tryshed.com, which prints compounded semaglutide from $159 a month and compounded tirzepatide from $239 in its banner, and $249 and $349 further down the same page.
- Was
- $99 a month on auto-refill
- Now
- $129 a month on auto-refill
- Why
- The card's starting price moved to $129 a month on 13 September, when Strut's semaglutide page was re-read, but its ongoing price still held the $99 that came from a Google description and is no longer on the page. The page prints "$129/mo" on auto-refill, with no lower price for staying on.
- Was
- Billing every 28 days is thirteen charges a year, not twelve, and the cheaper terms are paid up front.
- Now
- Found's pages disagree on how a longer plan is paid. Its plans page, joinfound.com/plans-and-pricing, says "Pricing based on 12-month plans paid up-front"; its offer terms, joinfound.com/terms/offer-terms-v3, price every plan length "per month, billed every 4 weeks (28-day cycle)", which is thirteen charges a year, not twelve. Before paying, ask Found whether a 12-month plan is charged all at once.
- Why
- The price note said Found's cheaper 3-, 6- and 12-month terms are paid up front. Read 13 September 2026, Found's own pages disagree: the plans page says "Pricing based on 12-month plans paid up-front", while the offer terms list every plan length at a price "per month, billed every 4 weeks (28-day cycle)". The note now gives both and tells the reader to ask Found before paying.
- Was
- The advertised $169 is a 12-month contract price. If you quit at month three you have still bought the year — read the cancellation clause before the first charge.
- Now
- Found's headline, from $99 a month on a 12-month plan, is the price with insurance, and that track adds a video-visit copay of about $30. Paying cash, the 12-month price is $169 and month to month is $289, all-in per 28-day cycle. Found's plans page says 12-month pricing is "paid up-front" while its offer terms bill "every 4 weeks", and neither prints a rule for leaving early: ask whether the year is charged at once, and what quitting before month 12 costs, before you pick the long plan.
- Why
- The line called $169 Found's advertised price and said that quitting at month three still buys the whole year. On 13 September 2026 Found's compounded semaglutide page advertises from $99 a month on a 12-month plan, which is the price with insurance; $169 is the 12-month price paying cash, and $289 is month to month. Found's own pages disagree on how the year is paid: its plans page says "Pricing based on 12-month plans paid up-front", while its offer terms bill every plan length every 4 weeks, and neither states a charge for leaving early. The line now gives both and says to ask before choosing the long plan.
- Was
- Covered, with no end date recorded
- Now
- Covered until 30 September 2026; from 1 October Rhode Island Medicaid stops paying for Foundayo, Saxenda, Wegovy and Zepbound prescribed only for weight loss
- Why
- An EOHHS memo of 5 August 2026 says that under the state's fiscal 2027 budget Rhode Island Medicaid will no longer cover certain GLP-1s prescribed solely for weight loss, beginning 1 October 2026, and names these four. The row said covered with no end recorded. Whether the non-GLP-1 weight-loss drugs stay covered is not yet confirmed: the preferred drug list could not be read on 13 September 2026.
- Was
- The state's decision tree denies at step two when there is no cardiovascular diagnosis — so in Texas the question is not your BMI, it is whether your heart disease is documented.
- Now
- Texas's current criteria, in force since 30 July 2026, approve Wegovy on two routes: documented cardiovascular disease with a diagnosis of obesity or overweight, for members 45 or older, or non-cirrhotic MASH with F2 to F3 liver fibrosis confirmed by biopsy or a non-invasive test within 180 days, for adults on the injection. Obesity alone is still denied, so in Texas the question is whether heart or liver disease is documented, not your BMI.
- Why
- The row cited Texas's October 2024 Wegovy criteria. The criteria in force for fee-for-service since 30 July 2026, Acentra's guide revised 8 May 2026, approve a second route beside cardiovascular disease: non-cirrhotic MASH with moderate to advanced fibrosis. In the current tree cardiovascular disease is step three, for members 45 or older, and MASH step four, so "denies at step two" no longer described it.
- Was
- $315 to $415 a month through telehealth
- Now
- No price shown: no seller on this site offers branded Saxenda at a published cash price
- Why
- The range came from Hone Health, counted here as a Saxenda seller. Hone's men's weight-loss page, read in a browser on 13 September 2026, sells "Compounded Liraglutide" at $160 a month plus membership, a compounded copy rather than Saxenda, so it no longer counts.
- Was
- $188 to $388 a month
- Now
- From $188 a month: the $39 membership plus medication from $149
- Why
- GoodRx's program page, read 13 September 2026, prints the $39 membership and medication "As low as $149". The $388 top added a $349 Wegovy pen price that page does not print; the GoodRx page that carried it could not be re-read.
- Was
- Branded, FDA-approved medication with no compounding risk
- Now
- Compounded liraglutide, not the FDA-approved Saxenda
- Why
- Hone's men's weight-loss page, read in a browser on 13 September 2026, lists "Compounded Liraglutide $160/mo + membership" and says "Compounded liraglutide is a daily injection". A compounded copy is not the FDA-approved product, and Hone had been counted as a seller of Saxenda.
- Was
- $315 to $415 a month
- Now
- $315 a month: the $155 membership plus $160 for liraglutide
- Why
- Hone's pages, read 13 September 2026, print the $155 membership and liraglutide at $160 a month. The $415 top of the range is printed on none of them.
- Was
- A three-month minimum
- Now
- Month to month: "a subscription service that you can cancel anytime"
- Why
- Eden's weight-loss page, read 13 September 2026, calls its membership "a subscription service that you can cancel anytime" and bills it monthly: "$39 for the first month, auto-renews at $99/month thereafter". The three-month minimum came from a third-party report.
- Was
- No price shown, because tryeden.com could not be read
- Now
- $198 a month for compounded semaglutide and $298 for tirzepatide: the $99 membership plus the medication
- Why
- Eden's weight-loss page was read on 13 September 2026 through a rendering service. It prices the medication at $99 a month for compounded semaglutide and $199 for compounded tirzepatide, and requires a membership of $39 for the first month, then $99 a month.
- Was
- $99 a month on auto-refill, $149 without it
- Now
- $129 a month on auto-refill for injectable semaglutide, $199 for the pill
- Why
- Strut's semaglutide page, read 13 September 2026, prints $129 a month on auto-refill for injectable semaglutide and $199 for a 30-day supply of oral semaglutide, consultations and shipping included. The $99 and $149 came from the descriptions Google showed for Strut's pages and appear nowhere on the page.
- Was
- $368 a month: a $19 membership plus Novo's $349 for Wegovy
- Now
- $498 a month after the first: LifeMD's $149 weight-loss program fee plus Novo's $349 for Wegovy
- Why
- The $19 is LifeMD+, LifeMD's general membership, not its weight-loss program. LifeMD's weight-management page, read 13 September 2026, charges $39 for the first month of the program and $149 a month after, and says medication cost is not included.
- 2026-09-13WegovyWegovy's weight at the start of the withdrawal trial, and the loss before randomization
- Was
- 106.8 kg at the start, the mean of all 902 enrolled, against 96.1 kg at randomization for the 803 randomized: a run-in loss of 10.7 kg, or 10% of body weight
- Now
- 107.2 kg at the start and 96.1 kg at randomization, both for the 803 randomized: a run-in loss of 11.1 kg, or 10.4% of body weight
- Why
- The page set the mean starting weight of all 902 people enrolled, 106.8 kg, against the mean weight at randomization of the 803 who went on, 96.1 kg. Table 9 of the label gives 107.2 kg at the start for those same 803, so the run-in loss is 11.1 kg, or 10.4% of body weight.
- Was
- Also the dose used for kidney and cardiovascular risk reduction.
- Now
- Also the maintenance dose for people with type 2 diabetes and chronic kidney disease, reached after at least 4 weeks at 0.5 mg.
- Why
- The schedule said 1 mg is the dose used for kidney and cardiovascular risk reduction. Section 2.2 of the label sets 1 mg as the maintenance dose only for people with type 2 diabetes and chronic kidney disease; the cardiovascular indication has no dose of its own.
- Was
- A daily injection means the gastrointestinal effects arrive daily rather than weekly, which is one reason it is tolerated less well than the weekly drugs. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced.
- Now
- In the adult trials 9.8% of people on Saxenda stopped because of side effects, against 4.3% on placebo, most often for nausea (2.9%), vomiting (1.7%) or diarrhea (1.4%). If a dose increase is not tolerated, the label says to consider waiting about one more week before the next one, which is a conversation with the prescriber rather than a reason to quit unannounced.
- Why
- The note said a daily injection is one reason Saxenda is tolerated less well than the weekly drugs. The Saxenda label, the page's only source, compares it with no weekly drug. What section 6.1 does report is now in its place: 9.8% of adults stopped because of side effects, against 4.3% on placebo.
- Was
- A tablet rather than an injection, and the same class effects: the route changes, the stomach does not. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced.
- Now
- A tablet rather than an injection, and the same class effects: the route changes, the stomach does not. In the two trials 8% stopped because of side effects, against 3% on placebo, 5% of them because of gastrointestinal ones. Nausea, vomiting and diarrhea were more common during dose escalation and decreased over time. Above 5.5 mg every step is optional, taken on response and tolerability, so the pace is a conversation with the prescriber rather than a reason to quit unannounced.
- Why
- The note said holding longer at one step is the standard answer, and that side effects are worst in the first days after each increase. Foundayo's label says neither: section 2.1 makes every step above 5.5 mg optional, on response and tolerability, and section 6.1 says nausea, vomiting and diarrhea were more common during escalation and decreased over time.
- Was
- This is the diabetes label. Prescribed for weight loss it is off-label, which changes nothing about the side effects and everything about whether a plan will pay. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced.
- Now
- This is the diabetes label. Prescribed for weight loss it is off-label, which changes nothing about the side effects and everything about whether a plan will pay. Gastrointestinal reactions made 3.1% of patients stop at 0.5 mg and 3.8% at 1 mg, against 0.4% on placebo, and most nausea, vomiting and diarrhea came during dose escalation. Side effects that do not settle are a conversation with the prescriber rather than a reason to quit unannounced.
- Why
- The note said stomach side effects are the reason most people stop and that holding a dose longer is the standard answer. Ozempic's label gives only the share who stopped because of them, 3.1% at 0.5 mg and 3.8% at 1 mg against 0.4% on placebo, and carries no instruction to hold a dose longer.
- 2026-09-13MounjaroMounjaro's schedule beside Zepbound's, and what its label says about stopping over side effects
- Was
- Same molecule as Zepbound at the same doses, on the diabetes label. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced.
- Now
- Same molecule and the same pen strengths as Zepbound, on the diabetes label, but a different schedule. Mounjaro goes up from 2.5 mg only if glucose control needs it, in 2.5 mg steps at least 4 weeks apart, and stops at 10 mg for children 10 and older. Gastrointestinal reactions made 3.0% of adults stop at 5 mg, 5.4% at 10 mg and 6.6% at 15 mg, against 0.4% on placebo, and most nausea, vomiting and diarrhea comes during dose escalation and eases over time. Side effects that do not settle are a conversation with the prescriber rather than a reason to quit unannounced.
- Why
- The note said Mounjaro is Zepbound at the same doses. Since the August 2026 label the schedules differ: Mounjaro rises from 2.5 mg only if glucose control needs it and stops at 10 mg for children, while Zepbound's 2.5 mg is not a maintenance dose. The note also called stomach side effects the reason most people stop and prescribed a longer hold at one step; Mounjaro's label gives only the rates at which they made people stop, and no such instruction.
- Was
- Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced.
- Now
- Most people who stop Zepbound because of side effects do so in the first few months, over gastrointestinal reactions such as nausea, vomiting and diarrhea. In the two weight trials 4.8% to 6.7% stopped because of side effects, rising with the dose, against 3.4% on placebo. Most nausea, vomiting and diarrhea comes during dose escalation and eases over time. If a maintenance dose is not tolerated, the label's answer is a lower maintenance dose, which is a conversation with the prescriber rather than a reason to quit unannounced.
- Why
- The note said holding a dose longer at one step is the standard answer to stomach side effects, and that they are worst in the first days after each increase. Zepbound's label says neither: section 2.1 says to consider a lower maintenance dose if one is not tolerated, and section 6.1 says most nausea, vomiting and diarrhea came during dose escalation and decreased over time.
- Was
- Ninety-nine of the 902 enrolled stopped during the 20-week run-in, most of them because of adverse reactions.
- Now
- Ninety-nine of the 902 enrolled stopped during the 20-week run-in; adverse reactions were the most common reason, for 48 of them.
- Why
- The page said most of the 99 people who stopped during the run-in did so because of adverse reactions. Section 14.2 of the label gives 48 of the 99: the most common reason, but not a majority.
- 2026-09-13ContraveWhether Contrave's side effects are gastrointestinal, and when opioids rule it out
- Was
- This is not a GLP-1: it is naltrexone plus bupropion, and its risks are neurological and cardiovascular rather than gastrointestinal. Anyone taking an opioid, including buprenorphine for addiction, cannot take it at all.
- Now
- This is not a GLP-1: it is naltrexone plus bupropion, and its boxed warning and main serious risks concern mood, seizures, opioid use and blood pressure. Its most common side effect is still nausea: in the trials 24% stopped because of an adverse event, against 12% on placebo, and nausea was the most common reason, at 6.3%. Anyone on long-term opioid treatment, including buprenorphine for addiction, cannot take it; for a short course of opioids it is paused, and lower opioid doses may be needed.
- Why
- The note said Contrave's risks are neurological and cardiovascular rather than gastrointestinal, and that anyone taking an opioid cannot take it at all. Section 6.1 of the label makes nausea the most common side effect and the most common reason people stop, at 6.3%. The contraindication covers chronic opioid use; for intermittent opioid treatment, section 5.4 says to pause Contrave.
- 2026-09-13VictozaRemoved: how liraglutide compared with weekly semaglutide and dulaglutide in trials
- Was
- Seven injections a week. Head to head, weekly semaglutide 1 mg lowered HbA1c and weight more than daily liraglutide 1.2 mg in SUSTAIN 10, but weekly dulaglutide 1.5 mg only matched liraglutide 1.8 mg on HbA1c in AWARD-6. It is here because it is still prescribed and still asked about.
- Now
- Seven injections a week. It is here because it is still prescribed and still asked about.
- Why
- The note reported two head-to-head trials, SUSTAIN 10 and AWARD-6, under a citation to the Victoza label alone. The label mentions neither trial nor either comparison drug; the results come from journal papers, so they have been taken off a schedule whose one source is the label.
- Was
- FDA prescribing information for ZEPBOUND, section 14.4
- Now
- FDA prescribing information for ZEPBOUND, section 14.1
- Why
- The citation named section 14.4. The current Zepbound label, published 2 September 2026, has no such section: its clinical studies run to 14.2, and Study 4, the withdrawal trial, is under 14.1. Every figure on the page matches 14.1; only the section number was wrong.
- Was
- Kidney or liver impairment of any degree caps the dose at 7.5 mg/46 mg
- Now
- Moderate or severe kidney impairment, or moderate liver impairment, caps the dose at 7.5 mg/46 mg; mild impairment changes nothing; on dialysis or with severe liver impairment, Qsymia is not to be used
- Why
- The schedule said kidney or liver impairment caps the dose at 7.5 mg/46 mg. Sections 2.4 and 2.5 of the label set that cap only for moderate or severe kidney impairment and moderate liver impairment. Mild impairment changes nothing, and for someone on dialysis or with severe liver impairment the label says not to use Qsymia at all, where the old line let 7.5 mg/46 mg read as allowed.
- Was
- The recommended dose. Escalation in children can take up to 8 weeks, and 2.4 mg is allowed if 3 mg is not tolerated.
- Now
- The recommended dose. For adults the lower doses are for titration only: an adult who cannot tolerate 3 mg stops Saxenda. Children 12 and older who cannot tolerate 3 mg may drop to 2.4 mg, and stop if that is not tolerated either; their escalation can take up to 8 weeks.
- Why
- The schedule said 2.4 mg is allowed if 3 mg is not tolerated, which read as applying to everyone. Section 2.2 of the label allows it only for children 12 and older. For adults the lower doses are for titration only, and an adult who cannot tolerate 3 mg stops the drug.
- Was
- …and who meet one of the demonstration's BMI and clinical categories.
- Now
- …BMI 35+, or 30+ with one of three conditions, or 27+ with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
- Why
- Read from medicare.gov/glp1bridge (which redirects to medicare.gov/coverage/weight-loss-drugs) on 12 September 2026. The line told a reader to find the criteria elsewhere; CMS publishes them: BMI 35+, BMI 30+ with diastolic heart failure, uncontrolled hypertension or stage 3a kidney disease, or BMI 27+ with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
- Was
- The recommended maintenance dose; 1.7 mg is the alternative if 2.4 is not tolerated.
- Now
- 1.7 mg is a maintenance dose in its own right on the label, chosen on response as well as tolerability.
- Why
- The step note said 1.7 mg is what you take if 2.4 mg is not tolerated. Section 2.2 lists 1.7 mg and 2.4 mg as the adult maintenance dosages, 2.4 mg recommended, and tells the prescriber to consider treatment response as well as tolerability when choosing between them.
- Was
- Contrave's label trial measured 5.4% weight loss against 20.9% in tirzepatide's own trial — separate trials, but a gap wide enough that the low price buys a materially weaker result.
- Why
- It was halfrx's own cross-trial comparison, which Currax does not publish; the program lists no condition beyond a prescription.
- Was
- Capped at $150 of savings a month and $1,950 a year. Without coverage the same card gives $499 a month, capped at $647 monthly and $8,411 a year.
- Now
- Capped at $150 of savings a month and $1,950 a year. Without coverage the same card lets you pay as little as $499 for a 28-day fill, with Lilly's savings in that case capped at $647 a month and $8,411 a year.
- Why
- Without coverage, $499 is what the patient pays for a fill and $647 a month caps Lilly's savings; the old wording read as if the card paid $499 and capped it at $647.
- Was
- Requires a commercial plan that already covers the Zepbound single-dose pen. Lilly's terms exclude anyone in a state, federal or government-funded program, and the list is longer than Medicare and Medicaid: Medicare Part D, Medicare Advantage, Medigap, DoD, VA and TRICARE are all named in it.
- Now
- The $25 needs a commercial plan that already covers the Zepbound single-dose pen. Without coverage the same card lets you pay as little as $499 for a 28-day fill of the single-dose pen, up to 13 fills a year, or for the KwikPen as little as $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up. Lilly's terms exclude anyone in a state, federal or government-funded program, and the list is longer than Medicare and Medicaid: Medicare Part D, Medicare Advantage, Medigap, DoD, VA and TRICARE are all named in it.
- Why
- The pages said that without coverage there was no copay for the card to reduce. Lilly's own terms give a separate rate for that case: as little as $499 for the single-dose pen and $299 to $449 for the KwikPen.
- Was
- The cheapest drug in the category by two orders of magnitude: pharmacies acquire it at $0.068 a tablet, about $2 for a 30-day supply, under the federal NADAC survey.
- Now
- Pharmacies acquire it at $0.068 a tablet, about $2 for a 30-day supply, under the federal NADAC survey. That is what a pharmacy pays, not what it charges you.
- Why
- $2 is what a pharmacy pays to acquire it, not a retail price, and against the next-cheapest retail price on the site ($66, Qsymia) it is about 33 times lower, not 100.
- Was
- Launched January 2026 — supply and pharmacy stocking are still uneven.
- Why
- The Novo release the line cited says "robust supply is on-hand", and no later source reports a shortage.
- Was
- The advertised $449 ceiling is conditional. It holds only while you refill within 45 days; lapse once and 10 mg and above cost $699 — 55% more than the number in the advert.
- Now
- The advertised $449 ceiling is conditional. It holds only while you refill within 45 days; lapse once and 10 mg and above cost $699 — 56% more than the number in the advert.
- Why
- $699 against $449 is 55.7% more, which rounds to 56%, not 55%.
- Was
- Generic liraglutide is now entering the market, which will push the price below every branded alternative.
- Now
- Generic liraglutide has been sold in the US since Teva launched generic Saxenda on 28 August 2025, so a branded Saxenda price is no longer the only liraglutide price.
- Why
- Teva announced FDA approval and the US launch of generic Saxenda on 28 August 2025, more than a year before the page said it was entering.
- Was
- $249 a month to start
- Now
- $297 a month, injectable semaglutide at every dose
- Why
- $249 is a different product, sublingual semaglutide tablets. Injectable semaglutide is $297 a month at every dose, so there is no cheaper start to quote.
- Was
- $169 a month to start
- Now
- $179 for the first month on the month-to-month plan, then $289
- Why
- $169 is charged only on a 12-month plan, and the comparison scores Found month to month; its month-to-month cash plan is $179 for the first month, then $289.
- Was
- Maximum dose is lower than Wegovy's 2.4 mg, so the achievable weight loss is smaller.
- Now
- Its top dose is 2 mg, against 2.4 mg for standard Wegovy and 7.2 mg for Wegovy HD; the Ozempic label reports no weight-loss percentage to set beside Wegovy's.
- Why
- The Ozempic drawback compared its 2 mg top dose with Wegovy's 2.4 mg. The current Wegovy label allows up to 7.2 mg once weekly (Wegovy HD).
- Was
- The whole escalation is four weeks, so unlike the GLP-1s the introductory price and the running price are nearly the same month.
- Now
- The dose changes and the bill does not: Currax's CurAccess program charges $99 a month for Contrave, with no price by dose. The escalation takes three weeks, and the full dose of two tablets twice a day starts in week 4.
- Why
- The page said four weeks. The label reaches the full dose at the start of week 4, after three weeks of escalation.
- Was
- The daily injection is the cost driver: a month is 30 doses rather than 4, which is why Saxenda rarely undercuts the weekly drugs even where its list price looks lower.
- Now
- Hone Health, the one seller halfrx records, charges $315 to $415 a month, and the price rises with the dose: $315 at the starting dose and $415 at maintenance. At $415 Saxenda costs more than Wegovy's $349 direct from NovoCare. The 30 daily injections a month change how often you inject, not the monthly price.
- Why
- The page said the daily injection count drives the price. Sellers charge by the month; Hone Health's price rises with the dose, from $315 at the start to $415 at maintenance.
- Was
- Seven injections a week for a molecule the newer weekly drugs beat on every trial figure. It is here because it is still prescribed and still asked about.
- Now
- Seven injections a week. Head to head, weekly semaglutide 1 mg lowered HbA1c and weight more than daily liraglutide 1.2 mg in SUSTAIN 10, but weekly dulaglutide 1.5 mg only matched liraglutide 1.8 mg on HbA1c in AWARD-6. It is here because it is still prescribed and still asked about.
- Why
- The page said the weekly drugs beat liraglutide on every trial figure. In AWARD-6, weekly dulaglutide 1.5 mg was non-inferior to daily liraglutide 1.8 mg on HbA1c (-1.42% against -1.36%), not better.
- Was
- Lilly sells it direct at $149 a month to start and $299 once titrated. The pill removes the injection, not the escalation: the top dose is at least 150 days away.
- Now
- LillyDirect self-pay reads $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, the lowest maintenance dose, and $299 at 9 mg and above. The 2.5 mg and 5.5 mg prices are reductions that end 31 December 2026, and the $299 at 14.5 mg and 17.2 mg holds only with a refill within 45 days; miss it and those two doses are $349. The pill removes the injection, not the escalation: the top dose is at least 150 days away.
- Why
- The page said $299 once titrated. 5.5 mg is a maintenance dose on the label, and LillyDirect prices it at $199 through 31 December 2026; $299 starts at 9 mg.
- Was
- Same molecule as Zepbound at the same doses, on a diabetes label. Which box it comes in decides whether insurance treats it as a required benefit or an excluded weight-loss drug — that, not the drug, is the difference in price.
- Now
- The dose changes and the bill does not: LillyDirect charges $499 a month self-pay at every strength from 2.5 mg to 15 mg. Zepbound, the same molecule at the same doses, is priced by dose there instead: $299 at 2.5 mg, $399 at 5 mg, and $449 from 7.5 mg if each refill comes within 45 days. The label matters for insurance: Mounjaro is approved for type 2 diabetes, and a plan that excludes weight-loss drugs can still cover it for that.
- Why
- The page said insurance status, not the drug, is the difference in price, and called Mounjaro a required benefit. Paying cash with no insurance involved, LillyDirect charges $499 for Mounjaro at every strength against $299 to $449 for Zepbound, and no rule requires a plan to cover Mounjaro.
- Was
- Ozempic tops out at 2 mg where Wegovy goes to 2.4 mg — the same molecule, a lower ceiling, and a label that does not mention weight. Prescribed for weight loss it is off-label, which is where the insurance argument starts.
- Now
- The first rise follows the fill count, not the dose: NovoCare, Novo's own pharmacy, charges a patient new to the Ozempic Savings Offer $199 for each of the first two fills at 0.25 mg or 0.5 mg, through 31 December 2026, then $349 a month at every dose up to 1 mg and $499 at 2 mg. Two milligrams is Ozempic's ceiling; Wegovy, the same molecule, goes to 2.4 mg, and to 7.2 mg (Wegovy HD) for weight reduction in adults. Ozempic is approved for type 2 diabetes, not weight, so prescribing it for weight loss is off-label, which is where the insurance argument starts.
- Why
- The page said Wegovy goes to 2.4 mg; its FDA label allows 7.2 mg once weekly for weight reduction in adults. The answer to "Does the price change as the dose goes up?" also gave no price: NovoCare charges $199 for two fills, then $349, and $499 at 2 mg.
- Was
- Cash only — no insurance is billed
- Now
- Accepts most insurance plans, with the copay calculated at checkout
- Why
- Amazon Pharmacy's home page, read 12 September 2026, says it "Accepts most insurance plans" and "We calculate your copay automatically"; the page said cash only, which nothing Amazon publishes supports.
- Was
- Read from TrumpRx, the federal price site, on the ground that Novo Nordisk publishes no cash price of its own
- Now
- Read from NovoCare Pharmacy, Novo's own: $349 a month for 0.25 to 1 mg, $499 for 2 mg
- Why
- The page attributed Ozempic's cash price to TrumpRx on the ground that Novo Nordisk publishes none. It does: NovoCare Pharmacy, Novo's own, lists $349 a month for 0.25, 0.5 or 1 mg and $499 for 2 mg, with $199 for a new patient's first two fills of 0.25 or 0.5 mg through 31 December 2026.
- Was
- BMI threshold: under the pilot, 30 or more, or 27 to 29.9 with a comorbidity
- Now
- No BMI threshold — Utah covers no GLP-1 for weight — with the pilot's terms described as history
- Why
- The pilot ended on 30 June 2026 and Utah now covers no GLP-1 for weight, so a threshold in that column told a reader there was a bar to clear when there is no route at all.
- Was
- Approvals granted before 1 January 2026 run out their six months; the new criteria apply at the first renewal
- Now
- They ran out by 30 June 2026, and the new criteria have applied at every renewal since
- Why
- A six-month approval granted before 1 January 2026 had expired by 30 June 2026, so the rule describes something finished rather than coming.
- 2026-09-11The boxed-warning deduction applied to every drug whose label carries one
- Was
- Only Contrave lost the 0.5 point /method publishes for a boxed warning
- Now
- All 11 drugs whose label carries a boxed warning lose it: Contrave and trulicity, wegovy-pill, foundayo-orforglipron, mounjaro, ozempic, zepbound, victoza, saxenda, wegovy, rybelsus
- Why
- The method has always listed a boxed warning at −0.5, and the drug pages print each label's boxed warning in red; the deduction reached only the one card that had been flagged by hand. It now follows the label text the pages already quote, so each of those drugs' scores falls by up to half a point.
- Was
- Novo has since also sued Hims over GLP-1 patents.
- Now
- Novo sued Hims for patent infringement in February 2026 and voluntarily dismissed the case on 9 March 2026.
- Why
- The docket shows a notice of voluntary dismissal filed on 9 March 2026; a case that ended a month after it began is not an open suit.
- Was
- Only the GoodRx offer that ended 31 March 2026
- Now
- Ozempic first-fill price: $199 for two fills through 31 December 2026, then $349
- Why
- TrumpRx, read 11 September 2026, runs the $199 for new self-pay patients between 17 November 2025 and 31 December 2026; the Ozempic page already quoted it, and the savings page listed only the expired GoodRx route.
- Was
- — a third of what Lilly allows on its cards for the same $25 headline.
- Now
- — two-thirds of the $150 Lilly allows on its Mounjaro and Trulicity cards, and the same as its Zepbound card, for the same $25 headline.
- Why
- $100 is two-thirds of $150, not a third.
- Was
- Contrave delivers about 6.4% weight loss against roughly 21% for tirzepatide, so the low price buys a materially weaker result.
- Now
- Contrave's label trial measured 5.4% weight loss against 20.9% in tirzepatide's own trial — separate trials, but a gap wide enough that the low price buys a materially weaker result.
- Why
- The Contrave page moved to the label's intention-to-treat 5.4% on 5 September; this line still gave the 6.4% from a trial the label does not carry.
- Was
- $70 a month on a 90-day prescription, $98 for a 30-day fill through Costco — the cheapest branded route on this site, and the one with a pregnancy test every month attached.
- Now
- $74.99 a month through Qsymia Engage home delivery at every dose, or $210 for 90 days — $70 a month; Costco members pay $65.99 for a 30-day fill. The cheapest branded route on this site, with a monthly pregnancy test recommended alongside it.
- Why
- The Qsymia page was corrected on 5 September — qsymia.com publishes no $98 — and this line still carried it.
- Was
- Four months of titration at $199 is the cheap part; month five onwards is the price you live with.
- Now
- The $199 covers the first two fills only; from the third month the price is the $349 you live with.
- Why
- The same sentence says the $199 is for the first two fills.
- Was
- LillyDirect self-pay reads $299 a month at 2.5 mg and $449 at the higher doses — and both hold only if you refill within 45 days; miss that and Zepbound lists at $699. So the escalation above is also a $150 price rise at week 5.
- Now
- LillyDirect self-pay reads $299 a month at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up. From 7.5 mg the $449 holds only if you refill within 45 days; miss that and 7.5 mg is $499 and 10 mg and above $699. So the escalation above is also a $100 price rise at week 5 and another $50 at week 9.
- Why
- The priced ladder on the same page puts 5 mg at $399, so the week-5 rise is $100, and the refill condition starts at 7.5 mg, where a lapse costs $499 rather than $699.
- Was
- the label says to restart escalation at a lower dose.
- Now
- the label says to restart escalation at the 0.8 mg starting dose.
- Why
- The label says to "reinitiate dosage escalation at the starting dosage"; "a lower dose" read as a step down rather than a restart.
- Was
- label published 2026-06-29
- Now
- label published 2026-06-30
- Why
- DailyMed's version history gives the date as Jun 30, 2026. It was read in a time zone ahead of UTC and recorded a day early.
- Was
- label published 2025-11-16
- Now
- label published 2025-11-17
- Why
- DailyMed's version history gives the date as Nov 17, 2025. It was read in a time zone ahead of UTC and recorded a day early.
- Was
- label published 2026-08-09
- Now
- label published 2026-08-10
- Why
- DailyMed's version history gives the date as Aug 10, 2026. It was read in a time zone ahead of UTC and recorded a day early.
- Was
- label published 2026-08-18
- Now
- label published 2026-08-19
- Why
- DailyMed's version history gives the date as Aug 19, 2026. It was read in a time zone ahead of UTC and recorded a day early.
- Was
- label published 2026-06-09
- Now
- label published 2026-06-10
- Why
- DailyMed's version history gives the date as Jun 10, 2026. It was read in a time zone ahead of UTC and recorded a day early.
- Was
- A negative pregnancy test is required before starting and every month afterwards, under an FDA REMS
- Now
- The label recommends a negative pregnancy test before starting and every month during treatment; the REMS restricts which pharmacies dispense it
- Why
- Section 5.1 of the label: "a negative pregnancy test is recommended before initiating QSYMIA and monthly during therapy".
- Was
- raised heart rate, raised blood pressure, insomnia, dry mouth, constipation, restlessness
- Now
- raised heart rate, raised blood pressure, restlessness, dizziness, insomnia, headache, dry mouth, diarrhea, constipation
- Why
- Section 6 of the label also names dizziness, headache and diarrhea; they were missing, so the comparison table showed them as absent from phentermine's label.
- Was
- reduced appetite
- Now
- decreased appetite
- Why
- Table 1 of the label says "Decreased Appetite"; the comparison table matched on that word and showed Mounjaro as not listing it.
- Was
- Six: nausea, diarrhea, vomiting, constipation, indigestion, abdominal pain
- Now
- Thirteen, in the label's order: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, burping, reflux, flatulence, hair loss
- Why
- Table 1 of the label published 13 August 2026 lists thirteen reactions in at least 5% of patients; the price page stopped at six, so the comparison table showed headache, fatigue, bloating, burping, reflux and hair loss as absent from Foundayo's label.
- Was
- Price conditional on refill timing
- Now
- Removed
- Why
- LillyDirect lists Mounjaro at $499 a month at every strength, with no refill window; the condition belongs to Zepbound and Foundayo.
- Was
- Overpriced for category
- Now
- Removed
- Why
- Lemonaid's $178 is a starting figure below the middle of the compounded range on this site, and no maintenance price is published to call high.
- Was
- A 12-month contract
- Now
- A six-month plan at $84 a month, or twelve months at $74
- Why
- WeightWatchers' plans page, read 11 September 2026, sells Med+ on a 12-month or a 6-month plan; both renew automatically.
- Was
- $179 a month after a $49 first supply
- Now
- $199 a month after a $79 first supply
- Why
- Noom's pricing page, read 11 September 2026. Its introductory prices are current, so the mark saying they had expired is removed.
- Was
- Cash only — no insurance is billed
- Now
- Visits are billed to insurance, and its team works to get the medication covered
- Why
- Knownwell's pricing page, read 11 September 2026: "knownwell visits covered by insurance" and "our insurance advocacy team will work to get you coverage whenever possible".
- Was
- $315 a month once titrated
- Now
- $415 a month, the top of its published range
- Why
- Hone's price scales with dose, so $315, the bottom of its $315–$415 range, is the starting dose; this site scores the maintenance price, and the Saxenda page already read it as $415.
- Was
- $149 at the 0.8 mg starting dose, $199 at the next step, $299 at higher doses (read 19 August)
- Now
- $149 at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 from 9 mg (read 11 September)
- Why
- The dosage ladder was corrected on 5 September and the note under the price still gave the August reading, with the 2.5 mg step at the wrong price.
- Was
- Overpriced for category
- Now
- Removed
- Why
- medvi.com has been a parked domain since 5 September 2026 and no price is shown, so there is nothing to call overpriced.
- Was
- $179–$297 a month
- Now
- $249–$297 a month
- Why
- Henry's price list, on henrymeds.com/legal/programs and last updated 3 December 2025, puts $179 on daily liraglutide injections, which this listing does not cover; its semaglutide is $249 as a tablet and $297 by injection.
- Was
- A $96 discount the page said ends 21 August 2026
- Now
- The same banner, still running on 11 September 2026
- Why
- Zealthy's page, read 11 September 2026, still carries it; a discount that does not end is not a price that expires.
- Was
- Price read from its own page
- Now
- Price from TrumpRx, the federal direct-purchase site
- Why
- The $199 and $349 are TrumpRx's figures; the page the provenance line matched was a GoodRx press release about an offer that ended on 31 March 2026.
- Was
- Month-to-month, cash only
- Now
- The $59 care price assumes a 12-month commitment, and insurance is accepted for weight-loss medications
- Why
- Both are printed on Sesame's own weight-loss page, read 11 September 2026: "Based on a 12-month Success by Sesame commitment" and "Insurance accepted for weight loss medications".
- Was
- $208 a month all-in once titrated, month-to-month, cash only
- Now
- $59 of care on a 12-month commitment plus medication from $149, with no maintenance price published; insurance accepted for the medication
- Why
- Sesame's own page, read 11 September 2026, prices the $59 on a 12-month commitment, lists the medication by dose — Wegovy pens $199 for two fills then $349, the Wegovy pill $149 then $299 — and says insurance is accepted for weight-loss medications. $208 was the cheapest pairing, not the dose anyone stays on.
- Was
- $149 a month, verified 2026-09-07
- Now
- No price: Novo publishes none for Rybelsus
- Why
- TrumpRx's $149 buys the Ozempic pill in 1.5, 4 and 9 mg tablets. Rybelsus is the 3, 7 and 14 mg tablet, and the label they share says the two are not interchangeable mg for mg — which the Rybelsus dosage page already said.
- Was
- Cited: COR-II: randomized phase 3 trial of naltrexone SR/bupropion SR
- Now
- Cited: FDA prescribing information for CONTRAVE
- Why
- The line "5.4% mean weight loss at 56 weeks in COR-I…" cited a source that does not contain it.
- Was
- Cited: CONQUER: phentermine plus topiramate, phase 3 (The Lancet)
- Now
- Cited: Qsymia Engage home delivery pricing, qsymia.com
- Why
- The line "$74.99/mo through Qsymia Engage…" cited a source that does not contain it.
- Was
- Estimated pricing — no published all-in figure.
- Why
- No estimate is shown; the next line already says Walgreens prices a visit and each drug separately.
- Was
- Dose-scaled on top of an already high base.
- Why
- Lemonaid publishes no price by dose, and its $178 starting figure is below the middle of the compounded range on this site.
- Was
- 12-month commitment on the cash tier. The longest lock-in of any major program.
- Now
- Six- or twelve-month plans only, and both renew automatically: $84 a month on six months, $74 on twelve.
- Why
- WeightWatchers' plans page, read 11 September 2026, sells Med+ on a 12-month or a 6-month plan.
- Was
- Month-to-month.
- Why
- Every Noom Med tier is "billed quarterly", per its pricing page read 11 September 2026.
- Was
- $349 is above LillyDirect's $299 Zepbound starter and well above Foundayo at $149.
- Now
- $349 a month at maintenance, against $299 for Foundayo and $449 for Zepbound once titrated through LillyDirect.
- Why
- The line set a maintenance price against Zepbound's starting dose.
- Was
- Dose-scaled on top of that base.
- Why
- Novo's $349 is one price across every standard Wegovy dose, so the total does not scale with dose.
- Was
- The cheapest drug in the category by two orders of magnitude: $0.068 a tablet at pharmacy acquisition cost against $263 for one Zepbound pen.
- Now
- The cheapest drug in the category by two orders of magnitude: pharmacies acquire it at $0.068 a tablet, about $2 for a 30-day supply, under the federal NADAC survey.
- Why
- The $263 for one Zepbound pen did not match the acquisition cost this site prints for Zepbound, and the comparison is not needed to make the point.
- Was
- $19.99 a month is the cheapest membership on this site by a factor of three, and the first month is free.
- Now
- $19.99 a month, among the cheapest memberships on this site, and the first month is free.
- Why
- LifeMD's membership is $19 a month on this site.
- Was
- Oral semaglutide lost 16.6% of body weight in OASIS 4 versus roughly 20%+ for tirzepatide injection — the convenience costs you efficacy.
- Now
- The Wegovy pill's label trial measured 13.6% weight loss, intention-to-treat — below tirzepatide injection's 20.9% in its own trial, so the convenience costs efficacy.
- Why
- 16.6% is not the intention-to-treat result; the Wegovy pill page on this site already gives the label's 13.6%.
- Was
- Cash only. If your plan covers Wegovy you would pay less going through insurance elsewhere.
- Why
- Knownwell's pricing page, read 11 September 2026: "knownwell visits covered by insurance", and its insurance team "will work to get you coverage whenever possible".
- Was
- New patients pay $199 for the first two fills through 31 December 2026, which covers most of the titration ramp.
- Now
- New patients pay $199 for the first two fills through 31 December 2026 — the first two of the four titration months.
- Why
- Wegovy's label steps the dose up every four weeks to reach 2.4 mg at week 17; two fills cover eight of those weeks, not most of them.
- Was
- About 14.9% mean loss in STEP 1 against roughly 20.9% for tirzepatide — meaningfully weaker.
- Now
- Weaker than tirzepatide where the two were tested head to head: in SURMOUNT-5, weight fell 13.7% on semaglutide against 20.2% on tirzepatide over 72 weeks.
- Why
- The line set Wegovy's own trial against Zepbound's, two trials in different populations, and cited a GoodRx press release for it. SURMOUNT-5 compared the two directly (Aronne et al., N Engl J Med 2025).
- Was
- $99/mo direct from the manufacturer's home delivery program — cheaper than every GLP-1 route on this site, branded or compounded.
- Now
- $99 a month direct from the manufacturer's home-delivery program — below every branded GLP-1 on this site, and tied with the cheapest compounded route.
- Why
- Strut Health's compounded semaglutide is also $99 a month on this site, so Contrave was not cheaper than every GLP-1 route.
- Was
- Topiramate raises the risk of oral clefts when taken in the first trimester. Qsymia is restricted under an FDA REMS requiring a negative pregnancy test before starting and monthly thereafter, plus effective contraception.
- Now
- Topiramate raises the risk of oral clefts when taken in the first trimester. The label recommends a negative pregnancy test before starting and every month during treatment, with effective contraception, and Qsymia is dispensed only through pharmacies certified under an FDA REMS.
- Why
- The label's words are "a negative pregnancy test is recommended before initiating QSYMIA and monthly during therapy"; the REMS restricts which pharmacies may dispense it, and does not itself impose the test.
- Was
- Approved down to age 12, where the newer agents have narrower labels.
- Now
- Approved down to age 12, as Wegovy and Saxenda are; Zepbound is for adults only.
- Why
- Wegovy's label is also indicated from age 12.
- Was
- Approved for adolescents aged 12 and over, where the newer agents have narrower labels.
- Now
- Approved for adolescents aged 12 and over, as Wegovy and Qsymia are; Zepbound is for adults only.
- Why
- Wegovy's label is also indicated from age 12, so "the newer agents have narrower labels" was not true of the one most readers compare it with.
- Was
- At $315+ through telehealth it costs more than Calibrate charges for branded Wegovy, which works far better.
- Now
- At $315 to $415 a month through telehealth it costs about what Wegovy does direct from NovoCare, $349, for roughly half the trial weight loss.
- Why
- Calibrate reads $548 a month on this site, not the $224 this line was written against.
- Was
- $315+ is more than Calibrate charges for branded Wegovy, which works substantially better.
- Now
- $315 to $415 a month for a daily injection with about half Wegovy's trial weight loss — Wegovy is $349 a month direct from NovoCare.
- Why
- Calibrate reads $548 a month on this site, not the $224 this line was written against.
- Was
- Foundayo (orforglipron) from $149/mo is the cheapest branded FDA-approved weight-loss drug available anywhere, and it is a daily pill.
- Now
- Foundayo (orforglipron) from $149 a month, the lowest self-pay price for a branded GLP-1 on this site, and a daily pill.
- Why
- Qsymia and Contrave are branded weight-loss drugs priced below $149 on this site, so "cheapest branded … available anywhere" was not true even here.
- Was
- $149/mo at the entry dose through LillyDirect is the lowest price for any branded FDA-approved weight-loss drug.
- Now
- $149 a month at the entry dose through LillyDirect — the lowest self-pay price for a branded GLP-1 on this site, matched only by the Wegovy pill's first month.
- Why
- Qsymia ($66–$75) and Contrave ($99) are branded, FDA-approved weight-loss drugs priced below $149 on this site.
- Was
- Flat price regardless of dose, month-to-month cancellation.
- Why
- medvi.com has been a parked domain since 5 September 2026; there is no price left for this to describe.
- Was
- Price climbs with dose — the $149 headline is the starter dose, not what you pay at maintenance.
- Now
- The $99 holds only on auto-refill; the same month without it is $149.
- Why
- The $99 and $149 are the same product with and without auto-refill, not a starting and a maintenance dose.
- Was
- Lowest verified all-in price in the market at the entry dose — $149/mo covers consult, medication and shipping.
- Now
- $99 a month on auto-refill, or $149 without it, covering the consult, the medication and shipping — the lowest published all-in price for compounded semaglutide on this site.
- Why
- Strut's pages price $99 a month on auto-refill and $149 without it, as the price page's price note records; the line still gave only the $149.
- Was
- Lilly publishes no cash price at all, so nobody paying without insurance can find out what it costs before the counter.
- Now
- Lilly publishes no cash price of its own; the $389 is the federal TrumpRx listing for the single-dose pen.
- Why
- The page prints $389 from TrumpRx beside a line saying nobody paying cash can find a price.
- Was
- Publishes no all-in price, so you cannot compare it against anything without starting an intake.
- Why
- Henry does publish its prices, on henrymeds.com/legal/programs, last updated 3 December 2025 — which the price page already says in its summary and its price note.
- Was
- The most-rated app of any seller here — 94,041 ratings on Apple's listing, against 14,746 for the next. That is a measure of how many people have used it, not of how well it works.
- Now
- Its iPhone app carries 94,685 ratings on Apple's listing, second only to PlushCare's among the sellers' own care apps — a measure of how many people have used it, not of how well it works.
- Why
- PlushCare's app has 144,662 ratings in the same read of Apple's listings on 11 September 2026, so Hims' was not the most-rated; its own count had also moved from 94,041.
- Was
- $99–$299/mo puts semaglutide within reach for people who would otherwise take nothing — the branded self-pay floor is $349.
- Now
- $99–$299 a month puts semaglutide within reach for people who would otherwise take nothing; branded semaglutide costs $299 a month for the Wegovy pill and $349 for the pens once past the starting doses.
- Why
- The Wegovy pill's maintenance dose is $299 through NovoCare, so $349 was not the branded floor.
- Was
- Supply can stop mid-titration. A court order or state action against your compounder ends your prescription with no notice — Mochi's affiliated pharmacy is under a Washington State Notice of Immediate Jeopardy.
- Now
- Supply can stop mid-titration. A court order or state action against your compounder ends your prescription with no notice — in March 2025 Washington's Pharmacy Commission issued a limited stop-service order against Aequita, the Kirkland pharmacy that then supplied Mochi Health.
- Why
- Aequita, the pharmacy this line meant, supplied Mochi until it closed in April 2026, so "is under" no longer described anything current; the Mochi page was corrected on 10 September and this line kept the old wording.
- Was
- A countdown sale on a prescription drug — $96 off, 'last chance', ending 21 August — is a retail tactic, not a price.
- Now
- A "$96 off — Last Chance: Sale ends soon" banner, still running on 11 September 2026 after the page said it would end on 21 August, is a retail tactic rather than a price.
- Why
- Zealthy's page, read 11 September 2026, still carries the banner three weeks after the end date it first gave.
- Was
- $199/mo cash price for pens under the GoodRx–Novo Nordisk agreement — the cheapest route to injectable semaglutide.
- Now
- New self-pay patients pay $199 for the first two monthly fills on TrumpRx, through 31 December 2026, then $349 a month at 0.25 to 1 mg.
- Why
- The GoodRx offer ended on 31 March 2026. TrumpRx's page, read 11 September 2026, offers $199 for two fills between 17 November 2025 and 31 December 2026, then $349 at 0.25, 0.5 or 1 mg and $499 at 2 mg.
- Was
- Negotiated cash price of $199/mo for Ozempic and Wegovy pens directly with Novo Nordisk — a manufacturer deal, not a coupon.
- Now
- Wegovy pens at $199 for the first two fills and $349 after, through GoodRx's agreement with Novo Nordisk — a manufacturer price rather than a coupon, with the $199 running to 31 December 2026.
- Why
- GoodRx's page, read 11 September 2026: "Wegovy pen offer applies only to first two fills at 0.25 or 0.5 mg doses and ends 12/31/26—price increases to $349 after the first two fills." It no longer offers Ozempic at $199.
- Was
- The headline $39/mo was an introductory rate that expired on 1 February 2026; the standard subscription is $119/mo. If you saw $39 in an ad, it is stale.
- Why
- GoodRx's own program page, read 11 September 2026, prices the membership at $39 a month with no end date and "Cancel anytime". The $119 came from an older report and appears nowhere GoodRx publishes.
- Was
- Cash only.
- Why
- Sesame's weight-loss page, read 11 September 2026, says "Insurance accepted for weight loss medications".
- Was
- No long-term contract.
- Why
- Sesame prices its $59 care fee "Based on a 12-month Success by Sesame commitment", on its own page read 11 September 2026; a shorter plan costs more.
- Was
- Cash only, no insurance route.
- Now
- Sesame's page says insurance is accepted for weight-loss medications, so the cash figure is not the only route.
- Why
- Sesame's weight-loss page, read 11 September 2026, says "Insurance accepted for weight loss medications".
- Was
- Requires a paid Costco membership on top.
- Why
- The price page already records that the weight-loss link on Costco's perk list goes to Sesame's ordinary public program, the same page a non-member reaches; no Costco membership is needed for it.
- Was
- Flat price that does not escalate with dose — at maintenance doses this beats the dose-scaled programs it looks expensive against.
- Why
- Sesame prices the medication by dose — on its own page, read 11 September 2026, the Wegovy pill is $149 at 1.5 mg and 4 mg and $299 above, and Wegovy pens $199 for two fills and $349 after.
- Was
- Flat $159/mo that does not increase as your dose escalates — unusual in compounded programs.
- Why
- shed.com has redirected to a domain broker since 30 August 2026, and the $159 was last verified on 10 June 2026; the pro was the price and nothing else.
- Was
- Flat $299 branded oral Wegovy with no GLP-1-specific subscription on top.
- Why
- samsclub.com/memberhealth has returned 404 since 21 August 2026 and the $299 could not be re-verified anywhere Sam's Club publishes; the pro was the price and nothing else.
- Was
- The $299 figure is an estimate, not a published all-in price — confirm before you rely on it.
- Now
- Amazon shows no GLP-1 price to a signed-out shopper — its Zepbound and Wegovy pages read "Currently unavailable" where a price would sit.
- Why
- The $299 was cleared from the card on 5 September 2026; this line still pointed at it.
- Was
- Telehealth programs mark it up hard: Ro at $373, Hims and LifeMD at $448 for a drug Novo sells at $149 to $299 depending on dose.
- Now
- Telehealth programs add a membership on top of the drug — Ro and Hims both charge $149 a month on a monthly plan — while Novo sells the pill direct at $149 to $299 depending on dose.
- Why
- Ro's $373 and Hims' and LifeMD's $448 were withdrawn or corrected between 19 August and 4 September 2026; neither Ro nor Hims publishes a medication price.
- Was
- $299 flat for compounded is worse than Calibrate's $224 for branded Wegovy at every dose.
- Now
- medvi.com has been a parked domain since 5 September 2026 — no pricing page and no program page left to buy from.
- Why
- The $299 was withdrawn on 5 September 2026 when medvi.com stopped serving a telehealth site, and Calibrate's $224 had also gone.
- Was
- Roughly $124/mo more than Calibrate for the same branded drug.
- Now
- Walgreens charges $49 per visit and prices each drug separately — Wegovy from $149 rising to $349 — so there is no single monthly figure to compare.
- Why
- Calibrate reads $548 and Walgreens publishes no monthly total; the $124 gap was arithmetic on two figures that no longer stand.
- Was
- $388 all-in makes it one of the most expensive routes to branded Wegovy tracked here — Calibrate is $224 for the same drug.
- Now
- $388 all-in is the $39 membership on top of a $349 fill — the same $349 Novo charges directly for Wegovy pens.
- Why
- Calibrate reads $548, not $224, so the comparison inverted; the $388 itself stands.
- Was
- $249+ for compounded semaglutide is $100/mo above Mochi and Found for the same molecule.
- Now
- The $249 standing rate follows a $129 first supply, and every tier bills quarterly, so the monthly figure is not what leaves your account.
- Why
- Found reads $289 a month and Mochi publishes only its membership, so the $100 gap this line claimed no longer exists.
- Was
- $373+ cash price is near the top of the market.
- Now
- WeightWatchers prices the membership and nothing else — $74 a month on the twelve-month plan — and publishes no figure for the medication on top.
- Why
- The $373 was withdrawn; since 30 August 2026 the card has held only the $74 membership, the one price WeightWatchers publishes.
- Was
- $373+ before dose escalation. You pay a premium for the brand relationships.
- Now
- Ro prices only the membership — $39 for a first month, then $74 a month prepaid annually or $149 monthly — and bills the medication on top without publishing what it costs.
- Why
- The $373 to $473 came from a third-party report and was withdrawn from the card on 4 September 2026; Ro publishes no total.
- Was
- $398+ estimated — among the highest tracked, and the marketplace structure means no single published price to hold them to.
- Now
- $208 is halfrx adding Sesame's $59 care fee to medication from $149 — Sesame publishes no combined figure, and the $59 assumes a 12-month commitment.
- Why
- Sesame's own page has read $59 plus medication from $149 since 21 August 2026, re-read on 5 September; the $398 estimate predates both.
- Was
- $408 is the second-highest flat price tracked.
- Now
- $208 a month all in — a $59 membership plus medication from $149 — and the medication half is a starting price, so higher doses cost more.
- Why
- The card has read $208 since 5 September 2026 — $59 plus $149 from Sesame's Costco pages — while this line still quoted $408.
- Was
- At $298+ you are paying branded-program money for a compounded product. Calibrate sells actual Wegovy for $224.
- Now
- $178 is a starting figure — the $49 membership plus $129 advertised as a limited-time rate — and no maintenance price is published, so the dose you stay on is unpriced.
- Why
- The card has read $178 since 20 August 2026 and Calibrate reads $548, not $224; the line quoted neither.
- Was
- $448+ ongoing is the joint-highest price tracked. The $188 first month is a promotional rate that ends.
- Now
- Hims never prices the membership and the medication together: $39 for a first month, $149 a month after, and the medication billed separately — so no monthly total is published to hold them to.
- Why
- The $448 to $548 came from a third-party report and matched nothing Hims publishes; it was withdrawn from the card on 4 September 2026 and this line kept it.
- Was
- $448+ ties Hims for the highest price tracked — you are paying for the PA team whether or not your plan would ever cover it.
- Now
- $368 a month once Novo's $349 is added to the $19 membership — you pay for the PA team's work whether or not your plan ever covers the drug.
- Why
- The card has read $368 since 19 August 2026 — LifeMD's $19 membership plus Novo's $349 self-pay — and Hims, the card this line said it tied, has carried no price since 4 September.
- Was
- $178 semaglutide, $278 tirzepatide, “flat whatever your maintenance dose”. Summary line: “$178 flat and month-to-month — with 1,200+ BBB complaints and two manufacturer lawsuits in court.”
- Now
- No all-in price: membership $79 a month, medication printed only as “as low as” $60 semaglutide and $90 tirzepatide
- Why
- Mochi lowered its medication prices and now prints them only as floors beside a dose list, varying by state. The $178 and $278 were the old $99 and $199 medication plus membership; both are struck through on Mochi's own page. A floor for an unnamed dose is not the monthly cost once titrated.
- Was
- $198–$298 a month, from a third-party report read on 10 June 2026
- Now
- No price
- Why
- tryeden.com has returned Cloudflare's block page to every reader since June, so the figure could not be checked against the seller for ninety-two days — twice the 45-day window this site holds itself to.
- Was
- No price. “Prices the medication and charges membership on top, and never publishes the fee.”
- Now
- $169 to $359 a month, medication included, billed every 28 days: semaglutide $289 month to month or $169 on a 12-month plan paid up front, tirzepatide $359 or $239
- Why
- The 30 August reading was of the homepage, which prices only brand-name drugs. Found's store pages publish the cash price for each compounded drug and plan length and say it covers care, medication and membership. Our daily price check now reads the pricing page.
- Was
- The FDA warning letter flag, with no letter under it on the record page
- Now
- The letter to Ivim Services LLC dba Ivim, 20 February 2026, shown with the flag
- Why
- The letter was matched and listed on /enforcement, but not attached to its page.
- Was
- FTC lawsuit against Hims & Hers: compliance analysis (frierlevitt.com), marked primary
- Now
- The FTC's own case page and complaint; the law firm's article kept as secondary
- Why
- An article about a complaint is not the complaint. The FTC's page names the plaintiffs — the FTC, California through Los Angeles County Counsel, and Utah's Division of Consumer Protection — which is also the record behind the state-action flag.
- Was
- F rating with the Better Business Bureau, with 25 of 208 complaints left unanswered. Active Eli Lilly lawsuit over its compounded tirzepatide marketing. Neither linked the BBB profile or the court docket.
- Now
- F rating with 27 of 233 complaints unanswered, read from the BBB profile on 10 September 2026; the Lilly suit cited to its docket, No. 4:25-cv-03536, open.
- Why
- The grade caps its score, and the page promises the document for each flag. The complaint count had also moved since it was read.
- Was
- Its affiliated compounding pharmacy is under a Washington State Notice of Immediate Jeopardy, plus two active manufacturer lawsuits.
- Now
- Aequita was ordered to stop compounding in March 2025; the two manufacturer lawsuits are cited to their court dockets, both open on 10 September 2026.
- Why
- Aequita closed in April 2026, so “is under” was no longer true. The order now named is the one the Department of Health published, a Limited Stop Service of 13 March 2025. The lawsuits had been cited to a comparison blog; they are now cited to the dockets.
- Was
- State action flag (“At least one state attorney general or regulator has an action on file”), which capped the score at 4.5, and a summary line naming “a state action against its pharmacy”
- Now
- No state action against Mochi is on file. Washington's March 2025 order was against Aequita Pharmacy, its supplier until Aequita closed in April 2026; the flag and its cap are removed, and the order is described on the page as what it was.
- Why
- A red flag on a company's page is a statement about that company. The only state action found was the Washington Pharmacy Quality Assurance Commission's Limited Stop Service against Aequita Pharmacy LLC. Aequita is a separate company and a co-defendant in Lilly's suit, not Mochi.
- Was
- FDA prescribing information for phentermine hydrochloride — Preferred Pharmaceuticals Inc., a repackager
- Now
- FDA prescribing information for phentermine hydrochloride tablets (Aurolife Pharma), version 8 of 15 June 2026
- Why
- A repackager publishes its own label document under its own DailyMed record, and it revises on its own schedule rather than the manufacturer's. Phentermine has 182 labels on DailyMed and nearly all of them are that; Adipex-P, the brand, is no longer listed. Aurolife Pharma holds an ANDA and publishes the document a claim about this drug should be traceable to. Every side-effect line recorded here was re-read against it before the citation moved, and all of them are in it.
- Was
- $299 branded oral Wegovy bundled into a membership you may already have.
- Now
- The Member Health program page stopped resolving; no price is left to verify.
- Why
- samsclub.com/memberhealth has returned 404 since 21 August 2026 and the page shows no price. The summary line still led with $299, a figure nothing published supports.
- Was
- Branded oral Wegovy at roughly $299 with no program to cancel.
- Now
- No membership and nothing to cancel — and no medication price until you are signed in.
- Why
- The $299 was a third-party tracker figure, cleared from the price page on 5 September 2026 because Amazon shows no GLP-1 price to a signed-out shopper. The summary line went on quoting it, which is the version most readers see in a search result.
- Was
- Strong prior-authorization team attached to a top-of-market $448 cash price.
- Now
- A prior-authorization team worth having, attached to a $368 month: $19 of membership plus Novo's $349.
- Why
- The price page has read $368 since 19 August 2026 — LifeMD's $19 membership plus Novo's $349 self-pay for Wegovy — while the summary line said $448.
- Was
- $298+ compounded semaglutide — priced like a branded program without being one.
- Now
- $178 to start: a $49 membership plus $129 of medication, and no maintenance price published.
- Why
- The price page has read $178 since 20 August 2026 — Lemonaid's own $49 membership plus its $129 limited-time medication rate — while the summary line said $298+, a figure nothing on the page supports.
- Was
- $328–$428, checked 2026-06-10
- Now
- no price
- Why
- The price page carried $328–$428 from a third-party price report read on 10 June 2026. CVS refuses this site's server address with a geographic block, so two re-checks read nothing at all; read from a residential connection on 10 September 2026, cvs.com/minuteclinic publishes a $29 eligibility check, an $89 virtual visit and medication "as low as" $149 with a manufacturer coupon or a $25 copay with insurance. None of those is an all-in monthly price, so the card now shows none.
- Was
- $125–$278, checked 2026-06-10
- Now
- $179–$299, checked 2026-08-19
- Why
- The $125–$278 shown here came from a third-party price report last read on 10 June 2026. The range is now taken from the sellers of compounded tirzepatide on this site — Noom at $179–$299 and Mochi at $278 — each read on its own page. Sellers that list tirzepatide without pricing it, such as Henry, contribute nothing rather than lending a figure that belongs to another drug.
- Was
- $149–$299, checked 2026-06-10
- Now
- $99–$299, checked 2026-08-19
- Why
- The $149–$299 shown here came from a third-party price report last read on 10 June 2026, and no page exists to re-read it against: compounded semaglutide is a category, not a product anyone sells under that name. The range is now the cheapest and most expensive published figures among the sellers of it on this site — Strut at $99, Zealthy at $151, Mochi at $178, Lemonaid at $178, Noom at $179–$299 and Henry at $249–$297 — each read on its own page, and it re-dates itself whenever one of them is re-read.
- Was
- $315–$415, checked 2026-06-10
- Now
- $315–$415, checked 2026-08-19
- Why
- The $315–$415 shown here came from a third-party price report last read on 10 June 2026. Novo publishes no cash price for Saxenda — saxenda.com and NovoCare offer an insurance check and nothing else — so the only cash figure that exists is what a telehealth program charges for liraglutide. The same range now comes from the Hone Health page, read on its own page on 19 August 2026, and moves when that reading moves.
- Was
- $388 all-in. The intro price was $39/mo — it became $119/mo on 1 February 2026.
- Now
- $388 all-in: a $39 membership plus $349 for the medication. GoodRx publishes both halves and never adds them.
- Why
- The summary line said the membership rose to $119 in February. The price note on the same page, read 4 September 2026, said $39 — and the $388 the summary line leads with is the $39 plus the medication, so the sentence disagreed with its own arithmetic. GoodRx's service page says "$39/mo. to start your weight loss treatment" and mentions no $119 anywhere.
- Was
- $199 a month, flat
- Now
- $199 for two fills, then $349 a month, or $499 at 2 mg
- Why
- The page's own note called the $199 introductory and the figure that means "what you pay once titrated" held it anyway — which is the substitution this site exists to expose. TrumpRx, already cited here, states the ladder in its own words, and the label gives the fill count: an Ozempic pen carries four once-weekly doses, so a year is 13 fills, not 12.
- Was
- Largest patient volume in the category, so the intake and shipping machinery is well tested.
- Now
- The most-rated app of any seller here — 94,041 ratings on Apple's listing, against 14,746 for the next. That is a measure of how many people have used it, not of how well it works.
- Why
- Patient volume is not something this site holds. What it holds is the rating count, which is a different measure — and the inference drawn from it, that the machinery is therefore well tested, was not evidence for anything. Replaced with the figure, its source, and what it does and does not show.
- Was
- label published 2026-06-18
- Now
- label published 2026-06-29
- Why
- No version of this label was ever published on 2026-06-18. DailyMed's version history for this document gives 2026-06-29 as version 19, and the date recorded here was the day we read it — Ozempic and phentermine both carried the same one. The wording was checked against the current label before this was changed: every section 5 heading has an entry here and every percentage quoted still appears there.
- Was
- label published 2025-10-14
- Now
- label published 2025-11-16
- Why
- No version of this label was ever published on 2025-10-14. DailyMed's version history for this document gives 2025-11-16 as version 31, and the date recorded here was the day we read it — Ozempic and phentermine both carried the same one. The wording was checked against the current label before this was changed: every section 5 heading has an entry here and every percentage quoted still appears there. The warning against sharing a pen was also listed last, where the label carries it near the top.
- Was
- label published 2026-06-16
- Now
- label published 2026-08-09
- Why
- No version of this label was ever published on 2026-06-16. DailyMed's version history for this document gives 2026-08-09 as version 62, and the date recorded here was the day we read it — Ozempic and phentermine both carried the same one. The wording was checked against the current label before this was changed: every section 5 heading has an entry here and every percentage quoted still appears there.
- Was
- label published 2026-01-30
- Now
- label published 2026-08-18
- Why
- No version of this label was ever published on 2026-01-30. DailyMed's version history for this document gives 2026-08-18 as version 14, and the date recorded here was the day we read it — Ozempic and phentermine both carried the same one. The wording was checked against the current label before this was changed: every section 5 heading has an entry here and every percentage quoted still appears there.
- Was
- label published 2026-08-19
- Now
- label published 2026-06-09
- Why
- No version of this label was ever published on 2026-08-19. DailyMed's version history for this document gives 2026-06-09 as version 20, and the date recorded here was the day we read it — Ozempic and phentermine both carried the same one. The wording was checked against the current label before this was changed: every section 5 heading has an entry here and every percentage quoted still appears there. The warning against sharing a pen was also listed last, where the label carries it near the top.
- Was
- no verified cash price is published
- Now
- $149 a month
- Why
- The price page cited TrumpRx, the federal direct-purchase site, naming this figure, and said in the same breath that nobody published one. The maker still does not — that sentence stays — but a government site does, and https://trumprx.gov/p/ozempic-pill publishes it as a tablet offer in its own page markup.
- Was
- no verified cash price is published
- Now
- $389 a month
- Why
- The price page cited TrumpRx, the federal direct-purchase site, naming this figure, and said in the same breath that nobody published one. The maker still does not — that sentence stays — but a government site does, and https://trumprx.gov/p/trulicity publishes it as a single-dose pen offer in its own page markup.
- Was
- The price check read the brand's own homepage, which carries no figure.
- Now
- the page linked below
- Why
- The page Sesame actually publishes the two halves on — $59 of care and medication from $149 — which is where the price page's $208 comes from. The Costco perk list it pointed at carries no weight-loss price at all.
- Was
- The price check read the brand's own homepage, which carries no figure.
- Now
- the page linked below
- Why
- TrumpRx prints a list price and a savings line for Ozempic, and their difference is $199 — the figure the price page already shows. It is a government page that publishes the number, where ozempic.com is a marketing site that does not.
- Was
- $159/mo compounded semaglutide, but you prepay the whole block up front.
- Now
- The domain is for sale and there is nothing left to read a price from.
- Why
- The price note and the summary line state the same fact in two places. The note already recorded that the figure had been withdrawn, and the summary line went on quoting it — on the price page and in every list that shows it.
- Was
- $299 flat compounded semaglutide, month-to-month.
- Now
- No longer a telehealth site: medvi.com serves a parked-domain stub.
- Why
- The price note and the summary line state the same fact in two places. The note already recorded that the figure had been withdrawn, and the summary line went on quoting it — on the price page and in every list that shows it.
- Was
- Branded oral Wegovy from $299, month-to-month, no compounding.
- Now
- Lists the manufacturers' own list prices and says it sets none of them; care is billed to insurance.
- Why
- The price note and the summary line state the same fact in two places. The note already recorded that the figure had been withdrawn, and the summary line went on quoting it — on the price page and in every list that shows it.
- Was
- $169/mo — but only if you sign for 12 months. Month-to-month costs far more.
- Now
- Prices the medication and charges membership on top, and never publishes the fee.
- Why
- The price note and the summary line state the same fact in two places. The note already recorded that the figure had been withdrawn, and the summary line went on quoting it — on the price page and in every list that shows it.
- 2026-09-05Walgreens Weight ManagementThe summary line still quoted a price the price page had withdrawn
- Was
- Branded Wegovy from about $348 through the pharmacy counter.
- Now
- Sells a visit and a fill rather than a month, so there is no monthly figure to compare.
- Why
- The price note and the summary line state the same fact in two places. The note already recorded that the figure had been withdrawn, and the summary line went on quoting it — on the price page and in every list that shows it.
- Was
- Compounded semaglutide from $175, locked behind a six-month prepay.
- Now
- Publishes a membership fee and a medication price and never a total, behind a six-month prepay.
- Why
- The price note and the summary line state the same fact in two places. The note already recorded that the figure had been withdrawn, and the summary line went on quoting it — on the price page and in every list that shows it.
- Was
- The serious reactions list did not mention pen sharing.
- Now
- Never share a pen between patients, even with a new needle (5.3) — sharing risks passing on blood-borne infection
- Why
- Each injectable label gives this its own heading in section 5. It is not part of the boxed warning, and it is the only harm on the label that falls on somebody other than the patient, so leaving it off the safety page left it nowhere on the site.
- Was
- The serious reactions list did not mention pen sharing.
- Now
- Never share a pen between patients, even with a new needle (5.9) — sharing risks passing on blood-borne infection
- Why
- Each injectable label gives this its own heading in section 5. It is not part of the boxed warning, and it is the only harm on the label that falls on somebody other than the patient, so leaving it off the safety page left it nowhere on the site.
- Was
- The serious reactions list did not mention pen sharing.
- Now
- Never share a FlexTouch pen between patients, even with a new needle (5.11) — sharing risks passing on blood-borne infection
- Why
- Each injectable label gives this its own heading in section 5. It is not part of the boxed warning, and it is the only harm on the label that falls on somebody other than the patient, so leaving it off the safety page left it nowhere on the site.
- Was
- The serious reactions list did not mention pen sharing.
- Now
- Never share a pen between patients, even with a new needle (5.4) — sharing risks passing on blood-borne infection
- Why
- Each injectable label gives this its own heading in section 5. It is not part of the boxed warning, and it is the only harm on the label that falls on somebody other than the patient, so leaving it off the safety page left it nowhere on the site.
- Was
- The serious reactions list did not mention pen sharing.
- Now
- Never share a KwikPen between patients, even with a new needle (5.10) — sharing risks passing on blood-borne infection
- Why
- Each injectable label gives this its own heading in section 5. It is not part of the boxed warning, and it is the only harm on the label that falls on somebody other than the patient, so leaving it off the safety page left it nowhere on the site.
- Was
- The serious reactions list did not mention pen sharing.
- Now
- Never share a KwikPen between patients, even with a new needle (5.10) — sharing risks passing on blood-borne infection
- Why
- Each injectable label gives this its own heading in section 5. It is not part of the boxed warning, and it is the only harm on the label that falls on somebody other than the patient, so leaving it off the safety page left it nowhere on the site.
- Was
- Covered, with prior authorization — on KFF's January 2026 analysis, with no criteria of Utah's own recorded
- Now
- Not covered for obesity: the weight-loss pilot's authorizations ran no later than 30 June 2026, and the state's own form stopped taking new obesity starts
- Why
- Utah's prior-authorization form is explicit that weight-management coverage was a legislative pilot that 'may not continue past 6/30/2026', caps every obesity authorization at that date, and by its 1 June 2026 revision routes an obesity request straight to a reauthorization section open only to people already approved during the pilot. The state's live criteria library now lists no weight-loss document at all. The aggregate status was right in January and was quoted three months after it expired.
- Was
- 30 or more, or 27–29 with two or more of dyslipidemia, hypertension, sleep apnea or type 2 diabetes
- Now
- The same, plus cardiovascular disease — one of the five the form lists, with seven ways of evidencing it
- Why
- The form's question 26B lists five risk factors and the coverage page listed four. Somebody with hypertension and a prior heart attack has two by the form's own count and had one by ours, which is the difference between qualifying at a BMI of 28 and not.
- Was
- No step-therapy requirement recorded
- Now
- A non-GLP-1 weight-loss drug must have been tried and failed first — 3 months without 10 lb on the stimulants, 6 months without 10 lb on orlistat — and the PDL's preferred product too
- Why
- The form has carried this since at least the 1 July 2026 revision, on the page after the BMI criteria, and the coverage page printed a blank where the state's hardest condition is. Virginia already sets the highest BMI bar of the covering states; the drug it makes you fail first is the other half of the answer.
- Was
- Not a threshold Texas publishes for obesity, because obesity is not an approvable reason
- Now
- No threshold for obesity alone, but the qualifying-diagnosis table at step three starts at Z68.27 — a BMI of 27.0
- Why
- Half of that was right: obesity alone is not approvable. But the criteria do carry a BMI floor, in the ICD-10 table behind step three, and somebody at a BMI of 26 with documented heart disease clears step two and fails step three. The coverage page read as though no number applied.
- Was
- Interim criteria of 1 August 2025: 30 or more, or 27 or more with a weight-related comorbidity
- Now
- The 1 September 2026 PDL criteria: over 30, or over 27 with a weight-related comorbidity
- Why
- The interim notice has been superseded. Wegovy and Zepbound are now in the permanent criteria document with the same structure and a stricter reading of the numbers — 'greater than 30', not 'greater than or equal to 30' — which decides the request of somebody at exactly 30. The same document is where the one-year approval length, previously recorded without a source, is actually stated.
- Was
- A reduced-calorie diet under way, or ongoing care from a registered dietitian nutritionist, and no other weight-loss drug at the same time
- Now
- Also a regimen of increased physical activity, unless a comorbidity makes it inadvisable
- Why
- The diet and the dietitian are alternatives to each other in the criteria; the activity regimen is a separate 'AND' and was missing from the coverage page. A prescriber documenting only the diet has documented two-thirds of what Minnesota asks.
- Was
- Wegovy and Zepbound criteria were rewritten at the same time to add the non-weight-loss indications
- Now
- The bulletin says the weight-loss criteria were to be rewritten and posted by MDHHS; it says nothing about the other indications
- Why
- Re-reading the bulletin on 5 September 2026, that sentence is not in it. What the bulletin says is narrower, and on a page about what a state will approve, a claim about which criteria were rewritten should not outrun the document it is attributed to.
- Was
- Wegovy is preferred; Zepbound and Saxenda need a documented Wegovy trial and failure
- Now
- The PDL's preferred drug has to be tried first, and 3 to 6 months of titration counts as that trial — the criteria document does not name which agent is preferred
- Why
- The criteria document sets the rule in the abstract and leaves the preferred agent to the PDL, which is a separate document and was not readable on 5 September 2026. Naming Wegovy went beyond the source, and the part a reader needs — that the trial is 3 to 6 months of titration, not a failed month — was missing.
- Was
- No renewal criteria and no renewal length recorded
- Now
- 5% or more renews for 6 months; 1–4% can get 3 months with a documented reason; under 1% is denied; maintenance runs 6 months at a time
- Why
- The criteria document sets all of it, on the pages after the initial-authorization section, and the coverage page stopped at the initial 6 months. The 1–4% band is the part a reader cannot guess: it is not a denial, but it needs a documented reason such as delayed titration.
- Was
- Kansas prints the comorbidity list rather than a second BMI threshold, so the numeric cut sits in the separate clinical criteria document the form links to
- Now
- The form does print one — a BMI of 40 for severe obesity — but only for the 'high cost' Table 4 agents, and it says Zepbound and Wegovy are not in that table
- Why
- The old sentence said the form prints no threshold. It prints one, in section III question 9A, and a reader who found it would have applied it to Wegovy or Zepbound and concluded they did not qualify at a BMI of 32. The note that the two GLP-1s sit outside Table 4 is on the same page of the same form.
- Was
- The numeric threshold sits in the clinical criteria rather than the PDL
- Now
- The threshold is in form PA04, Weight Management, and that file could not be retrieved on 5 September 2026 — three methods, all refused
- Why
- The old note left it sounding as though nobody had looked. The document exists and is named on the state's own prior-authorization page; what failed was our attempt to download it. Saying which document and what was tried is the difference between a gap a reader can close themselves and a shrug.
- Was
- No BMI threshold; the note said the clinical criteria sit outside the PDL so the threshold is not published in the document that lists coverage
- Now
- Adults 30, or 27–29.9 with one of eight named comorbidities; under 18 the 95th percentile — with 6-month approvals, 6-month renewals and a 5% (4% for adolescents) weight-loss test
- Why
- The threshold is published, in a different document: the DMAP prior-authorization form for GLP-1 agonists, revised 20 April 2026, which the pharmacy corner links from its prior-authorization forms list. The coverage page cited only the PDL, which carries the preferred list and no clinical criteria, and so printed 'not published' about a state that publishes it.
- Was
- Estimated - Amazon does not publish a single all-in figure. Verify at checkout.
- Now
- Amazon shows "Currently unavailable" where a GLP-1 price would sit and states it charges no monthly or sign-up fee; the medication half appears only after sign-in with a prescription on file
- Why
- "Verify at checkout" implied a shopper could reach the number. Read on 5 September 2026, they cannot: the Zepbound and Wegovy product pages show no price to a signed-out visitor, so the $299 on the price page cannot be checked by the reader any more than by us.
- Was
- Flat, does not scale with dose. $299 a month
- Now
- medvi.com is a parked domain: a noindex stub with no product, no company name in the body and no price. getmedvi.com will not load; its certificate has expired.
- Why
- Read on 5 September 2026. The figure was a third-party tracker's and had been dated 10 June; there is no longer a seller page to confirm it against. A price with no publisher is not a price.
- Was
- Flat. Requires Costco membership. $408 a month
- Now
- Costco's perk list carries no weight-loss or GLP-1 price; the weight-loss link goes to Sesame's ordinary public program at $59 a month for care plus medication from $149 a month
- Why
- Read on 5 September 2026: the Costco perk list on sesamecare.com covers primary care, therapy, fertility, check-ups, skincare, women's health and mental health medication, and stops there. A Costco member and a non-member reach the same weight-loss page at the same price. The $408 was a third-party tracker figure describing a Costco-exclusive price that the seller does not publish.
- Was
- No published all-in price. Third-party estimates run $297-$349 bundled - treat as unverified.
- Now
- Henry publishes a dated price list at henrymeds.com/legal/programs: $297 a month for injectable compounded semaglutide, $249 for sublingual tablets, $179 for daily liraglutide, $149 for phentermine
- Why
- The price page said this seller publishes nothing, and was marked as not publishing prices, while the seller's own site has carried a price list since 3 December 2025. It is filed under /legal/ rather than /pricing/, and henrymeds.com/pricing returns 404, which is how it was missed. Telling a reader a company hides its prices when it does not is the kind of error this site exists to avoid.
- Was
- $149 at the 0.8 mg starting dose, $299 at 14.5 mg and 17.2 mg. The $299 holds only with a refill inside 45 days; otherwise those doses are $349.
- Now
- $149 at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 at 9 mg, 14.5 mg and 17.2 mg. The 2.5 mg and 5.5 mg prices are temporarily reduced through 31 December 2026, and the $299 needs a refill inside 45 days.
- Why
- Lilly publishes six rungs on the Foundayo page and the price page carried two, so a reader at 5.5 mg saw no price at all. The page also marks the 2.5 mg and 5.5 mg figures with "Prices for the 2.5 mg and 5.5 mg dose are temporarily reduced through December 31, 2026", which the price page did not say. The $349 lapse price is dropped rather than restated: it is not on the price page, and lilly.com's full terms return 403, so it could not be re-read today.
- Was
- $98 a month, sourced from qsymia.com/pricing
- Now
- $74.99 for a 30-day supply, or $210 for 90 days — $70 a month, sourced from qsymia.com/patient/multiple-ways-to-save
- Why
- qsymia.com/pricing no longer exists; the server answers it with /?pagenotfound=/pricing. The savings page that replaced it publishes "A 90-day supply costs $210—just $70 per month" and "Patients pay $74.99 for a 30-day supply", and no $98 appears anywhere on the site. The catch also called the monthly pregnancy test a REMS requirement; the REMS restricts dispensing to certified pharmacies, and the monthly test is a labeling recommendation (Qsymia prescribing information, Highlights and section 5.1).
- Was
- $199 a month for Ozempic or Wegovy pens, for cash-paying patients using GoodRx. Described as an introductory price, with no end date.
- Now
- $199 a month for the first two fills at 0.25 mg and 0.5 mg, then $349. First-time GoodRx users only. Ended 31 March 2026.
- Why
- The press release the price page already cited carries the terms in its footnote: "Offer valid through March 31, 2026. Patients using GoodRx to save on their Ozempic or Wegovy prescription for the first time can pay just $199 per month for the first two fills. This introductory price applies to the two lowest doses (0.25 mg and 0.5 mg)." The offer had been over for five months and was still being listed as a live cash route.
- Was
- No published end date
- Now
- Ends 31 December 2026
- Why
- Lilly's Mounjaro card terms, read 5 September 2026, state "Card expires and savings end on 12/31/2026" against both the covered ($25, capped at $150 a month and $1,950 a year) and the non-covered ($499) block. The caps were right; the date was missing.
- Was
- No published end date. Requires your plan to cover Zepbound already. Not available to Medicare or Medicaid beneficiaries.
- Now
- Ends 31 December 2026. Excludes any state, federal or government-funded program — Medicare Part D, Medicare Advantage, Medigap, DoD, VA and TRICARE included.
- Why
- Lilly's card terms at zepbound.lilly.com/savings, read 5 September 2026, close every one of the three card blocks with "Card expires and savings end on 12/31/2026", and the eligibility list names seven government programs rather than the two the price page carried. A savings card with a published expiry was being shown with none.
- Was
- Known hypersensitivity to phentermine, topiramate or the sympathomimetic amines
- Now
- Known hypersensitivity to phentermine, topiramate or any other ingredient of Qsymia, or idiosyncrasy to the sympathomimetic amines. The label notes that anaphylaxis and angioedema have occurred with topiramate
- Why
- Section 4 lists five contraindications and the page had those five in the label's order, so nothing was missing and nothing was invented. The fifth was wrong in two ways: it dropped the excipients, so a reader reacting to an inactive ingredient would not have seen themselves in it, and it turned the label's separate 'idiosyncrasy to the sympathomimetic amines' into a hypersensitivity to them. Everything else the drug is famous for — the pregnancy test every month, the REMS, the suicidality warning — is in sections 5 and 8.1, not section 4, and it stays on the page where the label puts it.
- Was
- Five items: acute pancreatitis, severe gastrointestinal reactions, acute kidney injury, hypoglycemia, hypersensitivity reactions.
- Now
- Eight, in label order: acute pancreatitis (5.2), severe gastrointestinal reactions (5.3), acute kidney injury (5.4), hypoglycemia (5.5), hypersensitivity reactions (5.6), diabetic retinopathy complications (5.7), acute gallbladder disease (5.8), pulmonary aspiration under anesthesia (5.9).
- Why
- The first five headings were right and the last three were missing: diabetic retinopathy complications (5.7), acute gallbladder disease (5.8) and pulmonary aspiration under general anesthesia (5.9). None of the five carried the figures the label gives, and this is the newest label on the site, so it is the one most likely to be read against the source.
- Was
- Five items: acute pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury, pulmonary aspiration.
- Now
- Seven, in label order: acute pancreatitis (5.2), hypoglycemia (5.4), acute kidney injury (5.5), severe gastrointestinal reactions (5.6), hypersensitivity reactions (5.7), acute gallbladder disease (5.8), pulmonary aspiration under anesthesia (5.9).
- Why
- Severe gastrointestinal reactions (5.6) was missing, and it is the highest rate of any label on this site — 4.4% at 1.2 mg against 1.1% on placebo. Hypersensitivity (5.7) was missing too. 5.3 is the instruction not to share a pen, and 5.1 is the boxed warning printed above.
- Was
- Six items: acute pancreatitis, hypoglycemia, acute kidney injury, 'Severe gastrointestinal disease', diabetic retinopathy complications, pulmonary aspiration.
- Now
- Eight, in label order: acute pancreatitis (5.2), hypoglycemia (5.3), hypersensitivity reactions (5.4), acute kidney injury (5.5), severe gastrointestinal reactions (5.6), diabetic retinopathy complications (5.7), acute gallbladder disease (5.8), pulmonary aspiration under anesthesia (5.9).
- Why
- Both class headings were already here, but 5.6 was called 'Severe gastrointestinal disease' where the label says Severe Gastrointestinal Adverse Reactions, and the item gave no figure for a warning the label quantifies at 4.3% on the 1.5 mg dose. Hypersensitivity (5.4) and acute gallbladder disease (5.8) were missing outright.
- Was
- Six items: acute pancreatitis, diabetic retinopathy complications, acute kidney injury, gallbladder disease, hypoglycemia, pulmonary aspiration.
- Now
- Eight, in label order: acute pancreatitis (5.2), diabetic retinopathy complications (5.3), hypoglycemia (5.4), acute kidney injury (5.5), severe gastrointestinal reactions (5.6), hypersensitivity reactions (5.7), acute gallbladder disease (5.8), pulmonary aspiration under anesthesia (5.9).
- Why
- Pulmonary aspiration was already here; severe gastrointestinal reactions (5.6) and hypersensitivity (5.7) were not, and the six that were ran in an order the label does not use. The label quantifies the gastrointestinal warning by dose, 0.6% at 7 mg and 2% at 14 mg, which is the kind of figure the page exists to carry.
- Was
- Five items: acute pancreatitis, gallbladder disease, acute kidney injury, diabetic retinopathy complications, pulmonary aspiration.
- Now
- Nine, in label order, with the tablet's own figures: acute pancreatitis (5.2), acute gallbladder disease (5.3), hypoglycemia (5.4), acute kidney injury (5.5), severe gastrointestinal reactions (5.6), hypersensitivity reactions (5.7), diabetic retinopathy complications (5.8), heart rate increase (5.9), pulmonary aspiration under anesthesia (5.10).
- Why
- The tablets and the injection share one label, which reports several of these rates for each form separately — severe gastrointestinal reactions in 2% of tablet-treated adults against 4.1% of injection-treated, cholelithiasis in 2.5% against 1.6%. The price page had the injection's five headings and none of the tablet's numbers, and was missing 5.6, 5.7 and 5.9 like its sibling.
- Was
- Five items: acute pancreatitis, gallbladder disease, acute kidney injury, diabetic retinopathy complications, pulmonary aspiration.
- Now
- Nine, in label order: acute pancreatitis (5.2), acute gallbladder disease (5.3), hypoglycemia (5.4), acute kidney injury (5.5), severe gastrointestinal reactions (5.6), hypersensitivity reactions (5.7), diabetic retinopathy complications (5.8), heart rate increase (5.9), pulmonary aspiration under anesthesia (5.10).
- Why
- Section 5 runs 5.1 to 5.11 and the page carried five headings. Four were missing, including 5.9 Heart Rate Increase — a warning specific to this label, with an instruction to stop the drug if a raised resting heart rate persists, and one no other GLP-1 on this site has to carry. Severe gastrointestinal reactions (5.6) and hypersensitivity (5.7) were also absent. Figures are the injection's, which is what the price page shows.
- Was
- Five items: acute pancreatitis, diabetic retinopathy complications, gallbladder disease, acute kidney injury, hypoglycemia.
- Now
- Eight, in label order: acute pancreatitis (5.2), diabetic retinopathy complications (5.3), hypoglycemia (5.5), acute kidney injury (5.6), severe gastrointestinal reactions (5.7), hypersensitivity reactions (5.8), acute gallbladder disease (5.9), pulmonary aspiration under anesthesia (5.10).
- Why
- Section 5 runs to 5.10 and the page carried five headings. Severe gastrointestinal reactions (5.7), hypersensitivity (5.8) and pulmonary aspiration (5.10) were missing, and the retinopathy line gave no figure where the label gives 3.0% against 1.8%. 5.1 is the boxed warning and 5.4 is the instruction not to share a pen.
- Was
- Five items: acute pancreatitis, gallbladder disease, acute kidney injury, diabetic retinopathy complications, pulmonary aspiration.
- Now
- Eight, in label order: severe gastrointestinal reactions (5.2), acute kidney injury (5.3), acute gallbladder disease (5.4), acute pancreatitis (5.5), hypersensitivity reactions (5.6), hypoglycemia (5.7), diabetic retinopathy complications (5.8), pulmonary aspiration under anesthesia (5.9).
- Why
- Severe gastrointestinal reactions is 5.2, the first warning after the boxed one, and it was absent; so were hypersensitivity (5.6) and hypoglycemia (5.7), which the label reports at 10.3% for people also on a sulfonylurea. The five items that were there ran in an order the label does not use.
- Was
- Five items: acute pancreatitis, hypoglycemia with insulin or a sulfonylurea, hypersensitivity reactions, acute kidney injury, gallbladder disease.
- Now
- Eight, in label order: pancreatitis (5.2), hypoglycemia (5.3), hypersensitivity (5.4), acute kidney injury (5.5), severe gastrointestinal reactions (5.6), diabetic retinopathy complications (5.7), acute gallbladder disease (5.8), pulmonary aspiration under anesthesia (5.9).
- Why
- Section 5 runs 5.1 to 5.10 and the page carried five of its headings. Missing were 5.6 Severe Gastrointestinal Adverse Reactions, which the label quantifies and which is the reason it says Mounjaro is not recommended in severe gastroparesis; 5.7 Diabetic Retinopathy Complications; and 5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation, the warning a reader needs before booking surgery. 5.1 is the boxed warning, printed above in its own block, and 5.10 is the instruction not to share a pen.
- Was
- Oral Wegovy is $149 a month for 1.5 mg and 4 mg, but the 4 mg offer ends 31 Aug 2026 and reverts to $199
- Now
- $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg
- Why
- The 4 mg offer the note described as ending had ended, and the note never gave the 9 mg and 25 mg prices NovoCare publishes. The Wegovy pill page was corrected on 4 September; this company's page carried the same facts and was missed.
- Was
- $70 a month only on a 90-day prescription; a 30-day fill is $98 and only for Costco members
- Now
- $74.99 a month home delivery for anyone, $75 retail with the manufacturer discount, $65.99 for Costco members, $70 a month on a 90-day prescription
- Why
- qsymia.com on 5 September 2026 publishes those four figures and no $98. The manufacturer's own home-delivery price is open to anyone, so the page had the cheapest approved drug on the site both too expensive and behind a membership it does not need.
- 2026-09-05ContraveReplaced the serious reactions on the side-effects page with the label's section 5, in the label's order
- Was
- Five items, starting with seizures: seizures, raised blood pressure and heart rate, suicidal thoughts and behavior, angle-closure glaucoma, hepatotoxicity.
- Now
- The label's ten section-5 headings in order: suicidal thoughts and behavior; neuropsychiatric events reported with bupropion for smoking cessation; seizures; opioid overdose and precipitated withdrawal; increase in blood pressure and heart rate; allergic reactions; hepatotoxicity; activation of mania; angle-closure glaucoma; hypoglycemia in type 2 diabetes on antidiabetic therapy.
- Why
- Section 5 of the Contrave label has ten headings, 5.1 to 5.10, and the page carried five of them in an order the label does not use. The missing five include 5.4 Patients Receiving Opioid Analgesics, which says that trying to overcome the naltrexone block can be fatal. Blood pressure and heart rate stay: they are heading 5.5.
- 2026-09-05QsymiaReplaced the serious reactions on the side-effects page with the label's section 5, in the label's order
- Was
- Seven items: fetal harm, suicidal behavior and ideation, eye effects, mood and sleep disorders, cognitive effects, metabolic acidosis, and 'Raised heart rate'.
- Now
- The label's sixteen section-5 headings, each with the label's key fact: fetal harm with the monthly pregnancy test and the REMS; suicidal behavior and ideation; eye reactions; mood and sleep disorders; cognitive impairment; slowing of growth in 12- to 17-year-olds; metabolic acidosis; decrease in renal function; seizures on abrupt withdrawal; kidney stones; oligohidrosis and hyperthermia; hypokalemia; DRESS; serious skin reactions; anaphylaxis and angioedema; allergic reactions to FD&C Yellow No. 5. 'Raised heart rate' is gone.
- Why
- Section 5 of the Qsymia label runs from 5.1 Embryo-Fetal Toxicity to 5.16 Allergic Reactions Due to Inactive Ingredient FD&C Yellow No. 5, and heart rate is not one of its headings. The label reports the increase in heart rate under 6.1 Clinical Trials Experience, as an adverse reaction seen in trials, which is where this site's common-reactions list belongs and not a warning the label issues. Nine of the sixteen warnings were missing, including the one the page's own note describes: seizures on abrupt withdrawal.
- 2026-09-05MounjaroNamed the page the $499 was read from and what it requires, and dropped the claim that Lilly publishes no self-pay price
- Was
- Price note: "Read from Mounjaro's own pricing page on 24 Aug 2026: $499 for a one-month fill through the Mounjaro Savings Card". Drawback: "No published flat self-pay price, unlike Zepbound vials through LillyDirect."
- Now
- Read from LillyDirect on 5 Sep 2026: $499 a month self-pay at every strength from 2.5 mg to 15 mg, single-dose pens, prescription required, taxes and fees extra. There is no cheaper starting tier, unlike Zepbound's $299 at 2.5 mg. The same $499 is what the Mounjaro Savings Card charges for a 28-day, four-pen fill if you have commercial drug insurance that does not cover Mounjaro; the $25 figure Lilly's savings page leads with needs commercial insurance that does cover it and is capped at $150 of savings a month, so it is a copay offset, not a cash price. mounjaro.com/pricing redirects to that savings page.
- Why
- The note said the price was read from Mounjaro's own pricing page, but mounjaro.com/pricing redirects to Lilly's savings page, where $499 is a Savings Card price for people with commercial drug insurance that does not cover Mounjaro; that condition was not stated. Lilly's LillyDirect page, read 5 September 2026, lists $499 a month self-pay at every strength, which is the flat self-pay price the drawback said did not exist. Both pages are now among the sources, and each point for and against cites the source it rests on.
- Was
- FDA approved for type 2 diabetes. Weight loss is off-label use.
- Now
- FDA approved for type 2 diabetes: to improve glycemic control, and on the label revised August 2026 also to reduce the risk of cardiovascular death, heart attack and stroke in adults with type 2 diabetes at high risk of them. Weight loss is off-label use.
- Why
- Section 1 of Lilly's label revised August 2026 adds a second indication: to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk of them, on SURPASS-CVOT in section 14.6. The April 2026 version the site had been quoting carried glycemic control only.
- 2026-09-05MounjaroMoved the label link to Eli Lilly's own prescribing information and brought the dosing schedule up to its August 2026 revision
- Was
- The main page, the dosage page and the side-effects page linked the DailyMed record 0818426a, a repackager's copy (A-S Medication Solutions) of the April 2026 label, MOU-0011-USPI-20260422. The dosage ladder had a fixed step to 5 mg at week 5 and maintenance at 5 mg to 15 mg, reached at week 5 at the earliest.
- Now
- All three link Lilly's own label document, DailyMed record d2d7da5d, document MOU-0012-USPI-20260827, revised August 2026 and published on DailyMed 2 September 2026. The ladder starts at 2.5 mg and rises in 2.5 mg steps held at least four weeks only if glycemic control needs it, with no fixed week-5 step; maintenance reads 2.5 mg to 15 mg.
- Why
- A repackager's label document is a copy of the maker's label, and this one was a revision behind. Lilly's August 2026 label removed the sentence that 2.5 mg is not intended for glycemic control and the instruction to increase to 5 mg after four weeks. Sections 4, 5, 6.1, the boxed warning and the SURPASS-2 weight figures the site quotes (11.2 kg lost from a 93.8 kg baseline) are identical in both versions, so nothing else stored changed.
- Was
- Qsymia REMS: pregnancy testing and contraception requirements (FDA); CONQUER: phentermine plus topiramate, phase 3 (The Lancet); Qsymia CONQUER trial results (manufacturer HCP site); Assessment of the REMS for phentermine–topiramate (Annals of Internal Medicine); FDA prescribing information for QSYMIA
- Now
- Qsymia Engage home delivery pricing, qsymia.com; Qsymia REMS: pregnancy testing and contraception requirements (FDA); CONQUER: phentermine plus topiramate, phase 3 (The Lancet); Qsymia CONQUER trial results (manufacturer HCP site); Assessment of the REMS for phentermine–topiramate (Annals of Internal Medicine); FDA prescribing information for QSYMIA
- Why
- The price note said the figure was read from the maker's own page, but no such page was among the sources, so the page could not show where the price came from. The page is now cited; on 2026-09-05 it reads "$70 per month/$2.33 per day pricing applies to 90-day prescriptions only".
- Was
- GLP-1 weight loss cost 2026; FDA prescribing information for MOUNJARO
- Now
- Mounjaro savings and coverage, Lilly (self-pay $499 a month); GLP-1 weight loss cost 2026; FDA prescribing information for MOUNJARO
- Why
- The price note said the figure was read from the maker's own page, but no such page was among the sources, so the page could not show where the price came from. The page is now cited; on 2026-09-05 it reads "pay as low as $499 for a 1-month prescription".
- Was
- $149 a month, with the catch that the 4 mg price ends 31 August 2026 and becomes $199 and that Novo publishes no price at all for the 25 mg maintenance dose; end date 31 August 2026.
- Now
- $149 a month at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg, with the catch that $149 covers only the starting month and the maintenance dose is $299; no published end date.
- Why
- NovoCare prices every strength of the tablet, and nothing on its page carries an end date for the pill: the only dated offer there is the injection's $199 introductory price, through 31 December 2026. The recorded end date had passed, which made /coupons list the program as ended when it is still open.
- Was
- Summary line: $149 during titration; Novo does not publish what the 25 mg maintenance dose costs. Drawbacks: the $149 price on the 4 mg dose expires on 31 August 2026; Novo does not publish what the 25 mg maintenance dose costs.
- Now
- Summary line: NovoCare self-pay is $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and at the 25 mg dose you stay on. One drawback now says the $149 is the 1.5 mg month and the 25 mg month is $299; the drawback about an unpublished price is gone, and so is the marker that scored it zero on cost.
- Why
- The price range was corrected on 4 September and these lines were not. NovoCare's footnote reads: Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg. The 31 August date had passed, and the 25 mg price is published, so a drawback saying it was not and a marker withholding the cost score for the same reason were both contradicting the card's own price note.
- 2026-09-05PhentermineStopped claiming a 5% incidence threshold and a frequency table for a label that has neither, and added a missing contraindication on the side-effects page
- Was
- 'Reactions the label reports in at least 5% of patients' and 'A frequency table with exact percentages is in the label itself'. Contraindications listed seven items.
- Now
- The page says the label names its reactions by organ system, in prose, with no incidence rates, so there is no threshold and no table. Contraindications add 'Known hypersensitivity or idiosyncrasy to the sympathomimetic amines'.
- Why
- Section 6 of the phentermine label contains no percentages at all; the only '%' figures in the whole label are pharmacokinetic values in section 12. The reactions were on the label; the 5% claim was ours. Section 4 lists nine bullets and the page carried eight of them.
- 2026-09-05ContraveRewrote the contraindications on the side-effects page to match section 4 of the label
- Was
- Six items, including 'Pregnancy' and 'any condition that lowers the seizure threshold', and omitting other bupropion products, bulimia or anorexia nervosa, and allergy to the ingredients.
- Now
- The label's eight: uncontrolled hypertension; seizure disorder or history; other bupropion-containing products; bulimia or anorexia nervosa; chronic opioid, opiate agonist or partial agonist use, or acute opiate withdrawal; abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptics; MAOIs within 14 days; known allergy to bupropion, naltrexone or any component.
- Why
- Section 4 of the Contrave label lists those eight and nothing else. Pregnancy is handled in section 8.1, which says to discontinue when a pregnancy is recognized, not to withhold the drug; listing it as a contraindication overstated the label, while three real contraindications were missing.
- 2026-09-05SaxendaRemoved a suicidality warning and a pregnancy contraindication the label no longer carries, and corrected the common reactions on the side-effects page
- Was
- Serious: 'Suicidal behavior and ideation'. Contraindications included 'Pregnancy'. Common included 'reduced appetite' and an unqualified 'low blood sugar'.
- Now
- Serious: the label's current section 5 headings, which add severe gastrointestinal reactions, hypersensitivity and pulmonary aspiration. Contraindications: MTC or MEN 2 history, and serious hypersensitivity to liraglutide. Common: 'reduced appetite' removed; 'low blood sugar in people with type 2 diabetes'.
- Why
- Recent Major Changes on the Saxenda label: 'Contraindications, Pregnancy (4) (Removed) 05/2025' and 'Suicidal Behavior and Ideation (5.9) (Removed) 02/2026'. Section 4 now lists two contraindications. The adverse-reaction tables contain no appetite term, and the hypoglycemia row is 'Hypoglycemia in T2DM', footnoted to patients with type 2 diabetes not on insulin.
- 2026-09-05Wegovy pillRemoved the suicidality warning from the serious reactions on the side-effects page
- Was
- Suicidal behavior and ideation — the label says to monitor for it
- Now
- The line is gone; the remaining serious reactions are the label's current section 5 headings.
- Why
- The Wegovy label, which covers the tablet, records 'Suicidal Behavior and Ideation (5.10) (Removed) 02/2026' in its Recent Major Changes, and the word appears nowhere else in the current label.
- 2026-09-05WegovyRemoved the suicidality warning and added dysesthesia and hair loss to the common reactions on the side-effects page
- Was
- Serious reactions included 'Suicidal behavior and ideation — the label says to monitor for it'. The common list had 15 items and omitted dysesthesia and hair loss.
- Now
- The suicidality line is gone. The common list is the label's own 17-item list in the label's order, including dysesthesia (altered skin sensation, mostly at 7.2 mg) and hair loss.
- Why
- The Wegovy label's Recent Major Changes records 'Suicidal Behavior and Ideation (5.10) (Removed) 02/2026', and section 5 no longer contains it. The label's Highlights list of reactions at 5% or more includes dysesthesia and hair loss; in the 7.2 mg trials dysesthesia was 22% against 6% at 2.4 mg and 0.3% on placebo.
- 2026-09-05FoundayoRewrote the boxed-warning summary on the side-effects page to say what the label says about rodents
- Was
- In rodents this molecule caused thyroid C-cell tumors at human-relevant doses.
- Now
- The label carries the GLP-1 class boxed warning and says why it applies here: other GLP-1 receptor agonists that are active in rats and mice caused thyroid C-cell tumors; orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents; because it is active at the human GLP-1 receptor, the human relevance has not been determined.
- Why
- The boxed warning on the Foundayo label reads: 'Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents.' Section 13.1 adds that the 2-year rat study and the 26-week mouse study were both non-carcinogenic. Our sentence stated the opposite of the label it claimed to quote.
- Was
- The pages said they quoted the version published 2026-05-06.
- Now
- They quote the version published 2026-09-02 (Lilly document ZEP-0016-USPI-20260828, revised 08/2026), which is the current DailyMed version. The doses and reactions on the pages did not change between the two.
- Why
- DailyMed's version history for this record lists version 40 as published 2 September 2026, and the label text on file carries that revision. A page that names a superseded version is quoting a document the reader can no longer find.
- Was
- 15 mg once weekly (10 mg for children over 10)
- Now
- 15 mg once weekly (10 mg for children aged 10 and older)
- Why
- The Mounjaro label sets the pediatric dose for patients 10 years of age and older, inclusive. 'Over 10' excluded ten-year-olds the label includes.
- 2026-09-05QsymiaReplaced the missed-dose answer with the label's rule and corrected the week-12 note on the dosage page
- Was
- Missed dose: 'Take it in the morning; an evening dose causes insomnia. The 15/92 dose must be tapered rather than stopped, to avoid a seizure.' Step note: 'Escalation beyond it depends on weight lost by week 12.'
- Now
- Missed dose: wait until the next morning and take the usual dose, do not double up; the label says to avoid evening dosing because of the possibility of insomnia; the 15 mg/92 mg dose is tapered one capsule every other day for at least a week. Step note: after 12 weeks at 7.5/46 (about week 14 of treatment), an adult who has not lost at least 3% of body weight moves to 11.25/69 for 14 days, then 15/92.
- Why
- The Qsymia Medication Guide gives the missed-dose rule; the page had none. Section 2.2 evaluates after 12 weeks on 7.5 mg/46 mg, which starts on day 15, so the evaluation falls around week 14, not week 12, and the trigger is less than 3% of baseline weight lost. 'Causes insomnia' overstated 'the possibility of insomnia'.
- Was
- Saxenda is daily, so a missed dose is simply skipped — take the next one at the usual time, and do not double up.
- Now
- A single missed dose is skipped. If more than 3 days have passed since the last injection, the label says to restart at 0.6 mg and repeat the weekly escalation; the Medication Guide says to call the prescriber about how to restart.
- Why
- Section 2.1 of the Saxenda label: if more than 3 days have elapsed since the last dose, reinitiate at 0.6 mg daily and follow the escalation schedule. 'Simply skipped' was true only for a gap of up to 3 days.
- 2026-09-05FoundayoCorrected the maintenance dose, the week it is reached, and the missed-dose rule on the dosage page
- Was
- Maintenance dose: 9 mg, 14.5 mg or 17.2 mg daily, reached at the earliest in week 13. Missed dose: 'One tablet a day, swallowed whole, with or without food. Never two in a day.'
- Now
- Maintenance dose: 5.5 mg, 9 mg, 14.5 mg or 17.2 mg daily, reached at the earliest in week 9, with a note on the 5.5 mg step that it is the first dose the label does not require you to leave. Missed dose: take it as soon as possible, do not double up the next one, and after 7 or more consecutive missed doses restart escalation at a lower dose.
- Why
- Section 2.1 of the Foundayo label makes escalation mandatory only up to 5.5 mg (day 61); every step above is 'may be increased ... based on treatment response and tolerability', and 5.5 mg was a 72-week arm in both pivotal trials. Section 2.3 is the missed-dose rule the page had replaced with an administration sentence.
- Was
- The 'every dose on the price page is from' link went to the DailyMed record 27f15fac, which is the Rybelsus and Ozempic tablets label, with a 1.5 mg to 9 mg daily ladder.
- Now
- The link goes to DailyMed record adec4fd2, the Ozempic injection label the 0.25 mg to 2 mg weekly schedule was taken from.
- Why
- The doses on the page were always the injection's; the citation under them was the tablets'. A citation that leads to a different product is not a citation.
- 2026-09-05WegovyAdded the 7.2 mg (Wegovy HD) step, the missed-dose restart rule, and corrected the maximum dose on the dosage page
- Was
- Maximum dose: 2.4 mg once weekly. The ladder ended at 2.4 mg, the page said higher doses are not more effective, and the missed-dose answer covered a single missed dose only.
- Now
- Maximum dose: 7.2 mg once weekly (Wegovy HD) for weight reduction in adults; 2.4 mg for cardiovascular risk reduction, for ages 12 to 17 and for MASH. The ladder gains an optional 7.2 mg step from week 21 at the earliest. Missed dose: take it if the next one is more than 2 days away, otherwise skip; after 2 or more consecutive missed doses, restart escalation at a lower dose. The sentence about higher doses is gone.
- Why
- Section 2.2 of the Wegovy label: for patients who tolerate 2.4 mg for at least 4 weeks and need more weight reduction, the dosage may be increased to a maximum of 7.2 mg once weekly. The same label keeps 2.4 mg as the maximum for cardiovascular risk reduction and says the 7.2 mg dose is not established in pediatric or MASH patients. Section 2.4 adds the restart rule after 2 or more consecutive missed doses. Our page priced Wegovy HD in one paragraph and denied it existed in another.
- Was
- $1,046 a month: 4 × 0.5 mL at $522.89 per mL, from an entry effective 17 December 2025
- Now
- $1,077 a month: 4 × 0.5 mL at $538.48 per mL, effective 2026-08-19
- Why
- The NADAC file is cumulative — every weekly survey since December sits in it — and our import kept the cheapest entry it found rather than the one from the latest survey. The December figure had been superseded from the 14 January 2026 survey onward. The import now reads only the latest survey in the file.
- Was
- 1.5 mg $149, 4 mg $149, 25 mg unpublished — no year total, and a note that NovoCare published no price for the 25 mg dose
- Now
- 1.5 mg $149, 4 mg $199, 9 mg $299, 25 mg $299, one 30-tablet bottle a month: $3,338 in year one against the $3,588 that $299 times twelve implies
- Why
- NovoCare's self-pay footnote reads: patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg, one month being one bottle of 30 tablets. The $149 at 4 mg ended on 31 August 2026 as the old note said it would, and the label's Table 2 places a 9 mg step at days 61 to 90, which the ladder had skipped.
- Was
- 0.8 mg $149, 2.5 mg $199, then $299 from 5.5 mg with a $349 lapsed price on every fill from 5.5 mg: $3,338 in year one, $3,838 if the refill window was ever missed
- Now
- 0.8 mg $149, 2.5 mg $149, 5.5 mg $199, 9 mg $299, then $299 at 14.5 mg and 17.2 mg, one 30-tablet bottle a month: $3,188 in year one. Only the two top doses carry the 45-day refill condition, so the year after a missed window is $3,588
- Why
- Lilly's page prices 2.5 mg at $149 and 5.5 mg at $199, both reduced through 31 December 2026, and $299 first appears at 9 mg. Its footnote attaches the 45-day refill condition to 14.5 mg and 17.2 mg only; the 5.5 mg and 9 mg tiles carry no condition. The label requires at least 30 days at each of 0.8, 2.5, 5.5 and 9 mg before 14.5 mg, so at most eight of twelve bottles can be at a conditional dose. Lilly's page says regular prices apply after a lapse without printing them; the $349 is the figure this site recorded earlier and is unchanged.
- Was
- One line, 7.5 mg and above, with a lapsed price of $699 — $8,387 for the year if the refill window was ever missed
- Now
- 7.5 mg is $499 without the program and 10 mg and above are $699, so the year after a missed window is $8,137. The program year is unchanged at $5,637
- Why
- Lilly's terms give a regular price per dose: $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg and 15 mg. The table had applied $699 to the 7.5 mg fill as well, a $200 overstatement on a fill the label requires before 10 mg.
- Was
- COR-II, phase 3: 6.4% mean weight loss at week 56 against 1.2% on placebo
- Now
- 5.4% — COR-I on the label, 56 weeks: 5.4% mean weight loss on 32 mg/360 mg against 1.3% on placebo, intention-to-treat.
- Why
- COR-II does not appear on the Contrave label. The label carries three obesity trials — COR-I at 5.4%, COR-BMOD at 8.1% and COR-Diabetes at 3.7% — and the recorded figure was from none of them. COR-I is the plain trial of the drug against placebo, which is what the other entries in this ranking are.
- Was
- SCALE: about 8% mean weight loss over 56 weeks
- Now
- 7.4% — SCALE Obesity and Prediabetes, Study 1 on the label, 56 weeks: 7.4% mean weight loss on 3 mg against 3.0% on placebo, intention-to-treat.
- Why
- The label's intention-to-treat result for that trial is 7.4%. Rounding it up to 8% moved it past a number that was printed, in a column where sixth place and seventh place are less than a point apart.
- Was
- CONQUER and SEQUEL, phase 3: 6.6% to 8.6% mean weight loss at 56 weeks by dose
- Now
- 9.8% — CONQUER, Study 2 on the label, 56 weeks: 9.8% mean weight loss at the 15 mg/92 mg dose against 1.2% on placebo, intention-to-treat.
- Why
- This one understated. The label's own CONQUER result at the top dose is 9.8%, and its other obesity trial, EQUIP, reports 10.9%. The recorded range came from an analysis the label does not print, and it put Qsymia below Saxenda in the ranking when the label puts it above.
- Was
- SUSTAIN trials in type 2 diabetes; weight loss is a secondary endpoint, and the figure is about 12%
- Now
- 6.4% — No percentage of body weight appears anywhere on the Ozempic label, which has no weight-management section: its three trial sections cover glycemic control, cardiovascular outcomes and kidney outcomes, and all report weight in kilograms. This figure is worked out from the label's own kilograms — 6.4 kg lost from a 100.1 kg mean baseline at week 40 on 2 mg — and is an arithmetic step the label does not take.
- Why
- 12% is roughly double what the Ozempic label supports and appears nowhere on it. The label reports weight only in kilograms, and its largest is 6.4 kg from a 100.1 kg baseline, which is 6.4%. The 12% figure belongs to semaglutide at the 2.4 mg weight-management dose, which is Wegovy, not Ozempic.
- Was
- ATTAIN-1, phase 3: mean 14.7% body weight lost at the highest dose over 72 weeks
- Now
- 11.1% — ATTAIN-1, Trial 1 on the label, 72 weeks: 11.1% mean weight loss at 17.2 mg against 2.1% on placebo, intention-to-treat.
- Why
- 14.7% is the efficacy estimand published for ATTAIN-1 — the result modeled as if everyone had stayed on treatment. The label prints the intention-to-treat result for the same trial at the same dose and week, and it is 11.1%. The gap is 3.6 points, which is larger than the gap between two neighboring drugs in this ranking.
- Was
- SURPASS trials in type 2 diabetes; weight loss is a secondary endpoint
- Now
- 11.9% — No percentage of body weight appears anywhere on the Mounjaro label, which has no weight-management section: every trial on it is a diabetes trial and reports weight in kilograms. This figure is worked out from the label's own kilograms — 11.2 kg lost from a 93.8 kg mean baseline at week 40 on 15 mg, in SURPASS-2 against semaglutide — and is an arithmetic step the label does not take.
- Why
- The caveat was right and the number was not: the Mounjaro label states no percentage of body weight at all, so 15% could not have been quoted from it or from the SURPASS trials it names. The label's largest weight change is 11.2 kg from a 93.8 kg baseline, which is 11.9%. That division is now shown rather than hidden.
- Was
- OASIS 4, phase 3: 16.6% mean weight loss on 25 mg once daily when treatment was adhered to
- Now
- 13.6% — Study 7 on the label (NCT05564117), 64 weeks: 13.6% mean weight loss on 25 mg once daily against 2.4% on placebo, intention-to-treat.
- Why
- 16.6% is the adherent-population estimand from the published paper — what the trial found among people who kept taking the drug. The label prints the intention-to-treat result for the same trial, which counts everyone randomized, and it is 13.6% over 64 weeks rather than 72. Every other figure in this ranking is intention-to-treat, so the higher number was not comparable with the ones it was ranked against.
- Was
- FDA approved for cardiovascular risk reduction, chronic weight management, and MASH with moderate to advanced fibrosis
- Now
- The same three, with MASH marked as accelerated approval and the fibrosis stages named.
- Why
- The label states the accelerated approval and the confirmatory-trial condition in the same paragraph as the indication. Quoting the indication without it presents a conditional approval as a settled one.
- Was
- FDA approved for chronic weight management
- Now
- Cardiovascular risk reduction as well as chronic weight management, with the two differences from the injection named.
- Why
- The label gives the tablet its own indication list and it opens with the cardiovascular one. This site argues that a plan excluding weight-loss treatment cannot exclude the same drug under a cardiovascular indication, so understating the tablet's approvals weakened that argument for exactly the readers who need it.
- Was
- $149 to $199, with a note saying NovoCare published no price for the 25 mg maintenance dose
- Now
- $149 to $299, with $299 as the maintenance figure the score uses
- Why
- The old note was right on both counts and nothing acted on either. It said the 4 mg price held only until 31 August 2026, and that date passed four days before this correction; it said the 25 mg price was unpublished, and NovoCare now publishes it at $299. A page named for the 25 mg product was showing less than half of what that dose costs.
- Was
- $149 to $249 a month, from a third-party report dated 10 June 2026
- Now
- $99 on auto-refill, $149 without, from its own product pages.
- Why
- Strut publishes its medication price directly and mentions no membership. The recorded range was high at both ends.
- Was
- $388 a month, from a third-party report dated 10 June 2026
- Now
- $188 to $388, added by halfrx from GoodRx's own $39 membership and its own $149 to $349 medication prices.
- Why
- The old figure happened to be right and rested on nothing. It now rests on two numbers GoodRx publishes itself, with the arithmetic stated.
- 2026-09-04Walgreens Weight ManagementRemoved a monthly figure for a service that is not sold by the month
- Was
- $348 to $448 a month, from a third-party report dated 10 June 2026
- Now
- No monthly total. The price page gives the $49 visit fee and each drug's own price.
- Why
- Walgreens charges per visit and per fill. A monthly figure describes a subscription it does not sell.
- Was
- $373 to $473 a month, from a third-party report dated 10 June 2026
- Now
- No total. The price page gives the membership at $74 prepaid or $149 monthly, with the medication billed separately.
- Why
- Ro prices only the membership. The figure here was somebody else's attempt at a total and Ro publishes nothing to check it against.
- Was
- $448 to $548 a month, from a third-party report dated 10 June 2026
- Now
- No total. The price page gives the membership fee and says the medication is billed on top.
- Why
- Hims publishes a membership price and says in the same line that the medication is extra. No total appears anywhere on its own pages, and the range recorded here could not be reproduced from anything it states.
- Was
- $169 to $199 a month, from a third-party report dated 10 June 2026
- Now
- No total. The price page lists Found's published medication prices and notes the membership is charged on top.
- Why
- Found publishes brand-name GLP-1 prices starting at $650 a month, which cannot be reconciled with a $169 to $199 range. The membership fee is not published, so the total cannot be built and none is claimed.
- Was
- No price and no verification date
- Now
- No total, but the membership fee, the self-pay visit fee and the insured copay are now on the price page with the date they were read.
- Why
- The price page carried no figures at all. PlushCare publishes three of them; none is an all-in monthly price, so they are given as what they are.
- 2026-08-30WeightWatchers ClinicRemoved the price range and recorded the published membership fee instead
- Was
- $373 to $473 a month, from a third-party report dated 10 June 2026
- Now
- No total. The price page gives the Med+ membership fee and says the medication is charged separately.
- Why
- WeightWatchers publishes a membership price and no medication price. The range recorded here came from a third-party report and could not be reproduced from anything WeightWatchers states.
- Was
- $175 to $299 a month, from a third-party report dated 10 June 2026
- Now
- No total. The price page lists the membership fee and each medication price as Ivím publishes them.
- Why
- Ivím now publishes its own figures, which a third-party report cannot outrank. It publishes them as parts and never as a sum, and the page does not say whether the medication price includes the membership, so no total is asserted.
- 2026-08-30KnownwellRemoved the price range from the Knownwell page and moved its link to the new domain
- Was
- $299 to $399 a month, verified 10 June 2026
- Now
- No price. The price page explains what the new site publishes instead.
- Why
- The company moved from knownwell.health to knownwell.co and the figures that supported the recorded range are no longer published there. Re-reading found only a per-visit estimate with insurance, which is not the same measurement.
- Was
- $159 a month, verified 10 June 2026
- Now
- No price. The price page explains that the domain now resolves to a broker listing.
- Why
- The seller's domain stopped resolving to a business. Publishing a price for a company that cannot be reached is worse than publishing none, and the site's own rule is that an unverified figure is not shown.
- Was
- Listed as an Eli Lilly program sourced to LillyDirect, priced 'Published by Lilly on application', with no end date and tirzepatide as the only molecule
- Now
- A CMS demonstration at $50 a month running to 31 December 2027, covering all formulations of Foundayo and Wegovy and the KwikPen formulation of Zepbound — with the catch that the $50 counts toward neither the Part D deductible nor the out-of-pocket maximum
- Why
- Our own /insurance page already described the Bridge correctly, as a CMS demonstration at $50 a month, and cited CMS for it. The savings entry contradicted it on the same site: wrong sponsor, no price where a published one exists, and one molecule where three are covered. A reader landing on the savings page was told the price was not published while another page of ours stated it. The error came from reading LillyDirect, which mentions the Bridge, rather than the demonstration's own documentation.
- Was
- $299 a month all-in through Sam's Club Member Health, linked to samsclub.com/memberhealth
- Now
- Price unverified, with the price page explaining that the program page no longer resolves
- Why
- A weekly link check found samsclub.com/memberhealth returning 404. Nothing Sam's Club still publishes carries a bundled program price, and a figure whose source has disappeared is not a verified figure — so it comes down rather than sitting there aging quietly.
- 2026-08-19How every score is produced
- Was
- A number assigned by hand on each listing
- Now
- Arithmetic over the recorded facts, published in full at /method, recomputed whenever the data changes
- Why
- A rating a reader cannot check is not a rating. Converting it also exposed three ranking errors the hand-typed version had hidden, including compounded programs outranking branded ones on price alone.
- Was
- From about $149 a month
- Now
- $149 covers the 1.5 mg and 4 mg titration strengths only, and the 4 mg price ends 31 Aug 2026. Novo publishes no price for the 25 mg maintenance dose
- Why
- The $149 was a titration price presented as the price of the drug. It now scores zero on cost, because a maintenance price nobody publishes is not a cheap price.
- Was
- $299–$449 a month by dose
- Now
- $299–$699. The $449 ceiling holds only under the Zepbound Journey Program, which requires a refill within 45 days; without it 10 mg and above cost $699
- Why
- The advertised ceiling is conditional and we had published it as though it were fixed — the exact framing this site exists to strip out. Reading Lilly's own page also showed a month is defined as 28 days, so a year is 13 fills rather than 12.
- Was
- $349 flat for every standard dose, listed as a point in its favor
- Now
- $199 for the first two fills for new patients through 31 Dec 2026, then $349 for 0.25–2.4 mg and $399 for Wegovy HD 7.2 mg
- Why
- We had repeated the manufacturer's simplest framing. Reading NovoCare directly showed an introductory rate we had not mentioned and a high dose sitting outside the flat price entirely.
- Was
- $224 a month all-in, described as the cheapest legitimate route to branded Wegovy, and the highest-scoring listing on the site
- Now
- $199 membership plus roughly $349 for the medication — about $548 a month cash-pay, or near $224 if insurance covers the drug
- Why
- We had taken an all-in figure from a third-party tracker. Reading Calibrate's own pricing page showed it publishes the membership fee only and states that lab tests and prescription medication are not included. Auditing the rest of the category found the same everywhere: eight of eight readable pricing pages quote a membership fee or a medication price, never both. halfrx now adds the two itself and shows the arithmetic with a source for each half.
- Was
- 10% mean weight loss
- Now
- 6.6–8.6% by dose over 56 weeks (CONQUER and SEQUEL)
- Why
- The 10% figure was written from general knowledge without a source attached. Reading the published trial gave a lower and dose-dependent range. The price page had no source at all until this was fixed, which is the underlying failure — the number was wrong because nothing was holding it to account.